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Cancer is a growing problem. In the Netherlands, the twenty years prevalence of cancer 
is rising during the years. In 1990, 223 540 persons were living with cancer (twenty years 
prevalence). In 2002, the twenty years prevalence was 386 361 persons, and in 2010 
540 371 persons. The prevalence of cancer increased with 3% – 3.5% per year since 1990. 
This increase was mainly provoked by an increase in the national population, especially 
elderly1-2. 
In cancer patients, pain is one of the most frequent and feared symptoms3. Pain can 
interfere with all aspects of daily life and pain relief is an important component of pa-
tients’ quality of life. The prevalence of cancer-related pain remained stable over the 
years, although the knowledge on pain treatment did improve. For cancer patients with 
all disease stages, the studies before 1990 showed that the prevalence of cancer-related 
pain varied between 41% - 72%4-5, of whom 35% scored their pain as moderate to severe 
(pain intensity score ≥ 5)6. The studies between 1990 and 2005 showed a prevalence 
between 28% - 87%4-5, of whom between 23% - 65% scored their pain as moderate to 
severe7, and studies after 2005 reported a prevalence of 52% - 72%, of whom between 
20% - 56% scored their pain as moderate to severe8-10. The prevalence of pain in cancer 
patients is related to the stage of cancer. The review of Van den Beuken et al.5 showed 
that the prevalence of cancer-related pain was 33% (95% Confi dence Interval (CI) 
21-46%) in cancer patients after curative treatment (n=726); 59% (95% CI 44-73%) in 
patients during anti-cancer treatment (n=1408); and 64% (95% CI 58-69%) in patients 
with advanced disease (n=9763)5.
Cancer-related pain can be caused by (a) the direct growth and penetration by the 
tumor and/ or metastases (70%) (e.g. bone metastases, compression or infi ltration of 
nerves); (b) diagnostic procedures; (c) antitumor treatment, such as chemotherapy, sur-
gery or radiotherapy (20%); (d) and comorbidity or associated factors (10%) (e.g. consti-
pation, infections, muscular spasms)11-12. Cancer-related pain can be distinguished into 
nociceptive pain and neuropathic pain. Nociceptive pain is caused by tissue damage. 
This pain is often the result of bone metastases or infi ltration in soft tissues or viscera. 
Neuropathic pain can be defi ned as pain resulting from damage to the peripheral or 
central nervous system. Damage to the nervous system may be caused by compression 
or invasive growth by a tumor, by chemotherapy or after surgical interventions. About 
65%-68% of cancer-related pain is nociceptive and 8-9% is neuropathic. In 23-27% of 
cases both types of pain can be found12-15. 
The aim of pain management is to reduce the pain intensity to a tolerable level with 
acceptable side-eff ects. Cancer-related pain management consists of a combination 
of anti-tumor treatment (i.e. therapy directed at the cause of the pain) and pharmaco-
therapy. The aim of the anti-tumor therapy is to reduce tumor load with the intention 
to decrease patients’ pain intensity. Examples of the use of anti-tumor therapy are 
radiotherapy when patients have local pain due to bone metastases, or chemotherapy 
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in patients with potentially chemotherapy-sensitive tumors. Besides this, analgesic 
pharmacotherapy is the mainstay of cancer pain management. In 1986, the World 
Health Organization (WHO) published the analgesic ladder11. The WHO analgesic lad-
der categorizes analgesics into three steps which, depending on the pain intensity, 
progress from non-opioid analgesics (Step 1: acetaminophen and Non-Steroidal Anti-
Infl ammatory Drugs (NSAIDs)) to Step 2 opioids (e.g. codeine and tramadol), to Step 
3 opioids (e.g. morphine, fentanyl, hydromorphone). When patients have neuropathic 
pain, adjuvant analgesics like tricyclic antidepressants or anticonvulsants may help. The 
WHO ladder can be summarized in fi ve phrases: 
1. by the mouth (if possible, analgesics should be given by mouth; continuous subcu-
taneous infusion off ers an alternative route); 
2. by the clock (e.g. drugs should be taken at regular time intervals and not ‘as needed’); 
3. by the ladder (according the WHO analgesic ladder); 
4. for the individual (there are no standard doses for opioid drugs, the right dose is the 
dose that relieves the patient’s pain);
5. attention to detail (it is essential to monitor the patient’s response to the treatment 
to ensure that the patient obtains maximum benefi t with as few side-eff ects as pos-
sible)11-12,14. 
By the introduction of the WHO analgesic ladder, it was estimated based on practical 
experience that this approach combined with appropriate dosing guidelines would 
provide adequate pain relief to 70%-90% of patients11. In the years after this publication 
several studies evaluated the eff ectiveness of the WHO analgesic ladder. The two articles 
that reviewed these validation studies, questioned the feasibility and eff ectiveness of 
the analgesic ladder due to methodological limitations (e.g. small sample size or high 
rates of exclusion) of the included studies16,17. In these two validation reviews, adequate 
analgesia was described as a pain intensity of ≤ 4 measured with an NRS; description of 
pain intensity as none, slight or mild; or a ≥70% reduction of the pain intensity. Adequate 
analgesia was achieved in approximately 76% (range 45% - 100%) of the patients with 
cancer-related pain who were treated using the WHO analgesic ladder16-17.
In general, various reasons exist why patients’ pain is not always adequately managed 
(NRS ≥ 5, Figure 1). First, a substantial part of the cancer patients have complex pain 
problems. Approximately 35% of all cancer patients’ pain has a neuropathic component. 
Breakthrough pain occurs in 50%-65% of the cancer patients12,14. Besides this, not all 
patients could be treated eff ectively with oral morphine. For these patients, an opioid 
rotation, a change in opioid or route of administration has been shown to be benefi -
cial18-19. 
Secondly, health care providers do not always have enough knowledge regarding 
pain management and have various misconceptions about pain and pain treatment. 
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Physicians do not always follow the existing pain guidelines; the potential of anti-tumor 
therapy is not always included as an option. Besides this, not all physicians always 
pay attention to patients’ pain. In a recent pan-European survey of 5084 adult cancer 
patients, 72% reported to have pain9. In total, 56% of the surveyed patients rated their 
pain as ≥ 5 (on a 0-10 Numeric Rating Scale (NRS)). An in-depth survey to increase the 
understanding of cancer-related pain took place in a sample of 573 patients with NRS 
≥ 5, in whom 69% described that their pain interfered with daily life. Pain was primary 
managed by medical oncologists (42%) or general practitioners (19%). In only 5% of the 
patients a pain specialist or palliative care specialist was involved. According to these 
patients, the physician asked them about their pain at every consultation (55%), at most 
consultations (16%) or occasionally (22%)9. According to the patients, 38% believed that 
their physician mainly focused on their cancer, rather than the cancer-related pain, 33% 
believed that their physicians did not have time to discuss their pain and 26% thought 
that their physician did not know how to treat pain. Moreover, eleven percent of the 
patients with NRS ≥ 5 were not receiving any analgesics at all. Of the patients with a 
prescription of analgesics, only 40% received a prescription for WHO Step 3 opioids9.
Thirdly, besides health care providers, also patients have various misconceptions 
about pain and pain treatment, which could contribute to inadequate pain treatment. It 
is known that many patients have misconceptions about their pain and analgesics, espe-
cially concerns about opioid use, and a reluctance to report pain and to use prescribed 
analgesics20. 
AIMS 
Despite the existing guidelines and the increased attention for cancer-related pain, 
adequate pain management is still not possible for all cancer patients. The percentage 
of patients with adequate pain relief has a broad range and the reasons for inadequate 
WHO Cancer Pain Relief 
Guidelines 
Effective in 45% - 100% 
Complex pain problems: 
- neuropathic pain 
- breakthrough pain 
- morphine not always sufficient 
Professional barriers: 
- not following cancer pain guidelines 
- afraid of opioids 
- lack of attention for pain 
Patient barriers: 
- afraid of opioids 
- non-adherence 
- reluctance to report pain 
Figure 1. Reasons for inadequate pain relief
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pain relief are divers: patients with complex pain problems, misconceptions and insuf-
fi cient knowledge in both professionals and patients. Therefore attention to improve 
pain management remains necessary. 
This thesis describes research that was performed in order to get more insight in 
the factors that infl uence cancer-related pain management and research to evaluate 
interventions aimed to improve patients’ pain. The aims of this thesis are: 
1. to evaluate the prevalence of cancer-related pain and quality of cancer-related pain 
treatment at our own outpatient clinic;
2. to identify and summarize the available information on barriers hindering adequate 
pain management and interventions aiming to overcome these barriers;
3. to study methods to measure patients’ adherence to analgesics in cancer patients;
4. to evaluate whether an intervention based on the barriers hindering adequate pain 
management will improve patients’ pain intensity and interference in daily life; 
5. to evaluate whether an opioid rotation to parenteral hydromorphone will improve 
patients’ pain intensity in patients with complex pain problems. 
OUTLINE OF THIS THESIS
Chapter 2 describes a survey designed to determine the prevalence and quality of 
cancer-related pain in the outpatient clinic of the Erasmus MC Daniel den Hoed Cancer 
Center.
Chapter 3 describes a systematic review to identify the major barriers hindering ad-
equate pain management and the randomized controlled trials on interventions aiming 
to overcome these barriers (aim 2). 
Chapter 4 evaluates the feasibility of using Medication Event Monitoring System (MEMS) 
vials in comparison with medication diaries in cancer patients with chronic pain (aim 3). 
Chapter 5 reports the results of a randomized clinical trial in which we investigated if 
a pain consult combined with pain education including weekly monitoring leads to an 
overall reduction in average pain intensity over the 8-week study period (aim 4). 
In chapter 6 we describe the results of a retrospective study in advanced cancer patients, 
with a complex pain problem, who were rotated to parenteral hydromorphone (aim 5). 
Chapter 7 summarizes the main results of this thesis. Finally, the main conclusions and 
implications for clinical practice are discussed and recommendations for future research 
in pain management are given. 
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CH APTER 2
The eff ects of analgesic prescription 
and patient adherence on pain in a 
Dutch outpatient cancer population
Roelien H Enting
Wendy H Oldenmenger
Arthur R Van Gool
Carin CD van der Rijt
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Journal of Pain and Symptom Management, 2007; 34: 523-531
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ABSTRACT
Insuffi  cient awareness of cancer pain, including breakthrough pain, inadequate anal-
gesic prescriptions, and nonadherence contribute to inadequate cancer pain manage-
ment. There are insuffi  cient data about the contribution of each of these factors. In a 
cross-sectional survey among 915 adult cancer outpatients, pain was assessed by the 
Brief Pain Inventory. Breakthrough pain was defi ned as a worst pain intensity rated as ‘7 
or more’ and an average pain intensity rated as ‘6 or less’ in patients on ‘around-the-clock’ 
(ATC) analgesics. The Pain Management Index (PMI) was calculated to measure the qual-
ity of treatment. Adherence was considered inadequate when below 100% of the dose 
prescribed. Pain was present in 27% of patients. Worst pain was rated as moderate in 
26%, and as severe in 54%. Breakthrough pain was present in 45% of patients with ATC 
medication. The PMI indicated inadequate treatment in 65% of patients. The propor-
tions of patients’ adherent to ATC analgesics varied from 59% (tramadol) to 91% (Step 
3 opioids). The management of cancer pain will benefi t most from improving analgesic 
prescriptions and patient adherence. 
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INTRODUCTION
Cancer pain management is complex and consists of anticancer treatment, analgesics, 
adjuvant analgesics (e.g., anti-epileptic drugs for neuropathic pain), and strategies to 
improve side eff ects 1-4. The selection of the appropriate analgesic therapy is based on 
the intensity of the pain according to the three-step analgesic ladder of the World Health 
Organization (WHO)5. Analgesics should be given around the clock (ATC). In addition, 
patients may need supplemental rescue doses for breakthrough pain4-5. Accurate knowl-
edge of the prevalence of pain among cancer patients is vital to improve treatment of 
cancer pain. In the past 10 years, the Pain Management Index (PMI) was developed as 
a simple and objective tool for evaluating the quality of analgesic prescriptions, and 
breakthrough pain was recognized as a separate entity6-7. 
The PMI is a composite measure computed by subtracting a patient’s worst pain 
intensity from the rating of the most potent analgesic prescribed7. The PMI is consid-
ered a conservative estimate, since it does not take into consideration the doses of the 
analgesics used or the schedule (ATC or ‘as needed’ [PRN]). The PMI is the single most 
often used outcome measure for quality of pain treatment7-21.
Breakthrough pain was originally described as a transitory exacerbation of pain to 
greater than moderate intensity that occurs in addition to otherwise stable persistent 
pain of moderate intensity or less among patients on stable doses of opioids1. The defi -
nition of breakthrough pain, however, diff ers between research groups6. Breakthrough 
pain is associated with greater functional impairment, and more pain-related hospital-
izations and physician offi  ce visits22-23. 
Even though health care providers mention nonadherence as one of the most com-
mon reasons for uncontrolled cancer pain, surprisingly little attention has been paid 
to this issue24. The few studies that measured adherence to analgesic regimens among 
cancer patients reported adherence rates for fi xed-schedule opioids averaging 80 – 
90%25-26. Even fewer data are available about adherence to nonopioid drugs in cancer 
patients. Furthermore, it has been demonstrated outside the fi eld of cancer pain that 
simple measures of adherence, e.g., patient’s self-report, are useful since they correlate 
with clinical outcome27-29.
The present cross-sectional study was designed to determine the prevalence of pain, 
including breakthrough pain; to assess the quality of pain management; and to evaluate 
adherence to ATC analgesics in a cohort of outpatients treated in a tertiary cancer center 
in Rotterdam, The Netherlands. 
Wendy Oldenmenger bw.indd   17 08-11-11   10:32
18 Chapter 2
METHODS
Study subjects
During one week, we studied 915 adult outpatients with cancer. All patients were treated 
in the Daniel den Hoed Cancer Center in Rotterdam, the 136-bed tertiary cancer center 
of the Erasmus Medical Center, Rotterdam, the Netherlands. The study was approved by 
the Medical Ethics Committee of the Erasmus Medical Center. All patients gave written 
informed consent. 
Study procedure
Sixteen advanced medical students were trained by two of the authors (RHE, WHO) to 
interview the patients. A pain questionnaire was developed for the purpose of this study. 
The following sociodemographic and medical variables were collected for all participat-
ing patients: age; gender; Eastern Cooperative Oncology Group (ECOG) Performance 
Status30; year and month of cancer diagnosis; type of cancer; tumor status (no evidence 
of disease [NED], locoregional, or distant metastases); current (previous six weeks) anti-
tumor treatment; intent of current anti-tumor treatment (curative or palliative, accord-
ing to the treating physician); and use of bisphosphonates. All data were checked by 
one of the authors (RHE). Subsequently, the interviewer asked the patients if they had 
experienced pain in the past week other than everyday kinds of pain. This represents 
the fi rst question of the Brief Pain Inventory (BPI)- Dutch Language Version31. In addition, 
patients were asked if they had been prescribed any analgesic. All patients who had pain 
or were taking analgesics were asked to fi ll in the written part of the questionnaire. After 
completion, the questionnaire was checked and patients received additional questions 
about their analgesic use. If patients were unable to give details about current analgesic 
use, a telephone call was made in the following days to complete the questionnaire. 
Measures
Pain, Pain Interference with Activities, and Breakthrough Pain
The questionnaire started with the BPI- Dutch Language Version31. Patients were asked 
to rate their present pain on an 11-point numeric pain rating scale of 0-10, and their 
least, worst, and average degree of pain in the past week. They were asked to rate how 
much their pain interfered with level of activity, mood, ability to walk, work, relations 
with others, sleep, and enjoyment of life on a four-point scale commonly used in 
protocols of the European Organization of Research and Treatment of Cancer (EORTC) 
(not at all, a little, quite a bit, very much)31. Breakthrough pain was operationalized as a 
worst pain intensity rated as ‘7 or more’ superimposed on controlled background pain 
(average pain intensity rated as ‘6 or less’). We included patients using all kinds of ATC 
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medication instead of ATC opioids, contrary to the defi nition used by Portenoy et al., but 
in accordance with other research groups1,22. 
Analgesics 
Each patient was asked to describe current prescriptions for analgesics (PRN and / or 
ATC, drugs, doses, and routes used). Analgesics were categorized as WHO Step 1 (non-
steroidal anti-infl ammatory drugs [NSAIDs], acetaminophen), WHO Step 2 (tramadol, 
codein), WHO Step 3 (morphine, fentanyl patch, oxycodone, methadone), or WHO ‘Step 
4’ (invasive opioids)5. The opioid dose was converted to oral morphine equivalent dose 
using published analgesic tables23,32. The median oral morphine equivalent doses were 
calculated for the total dose prescribed (ATC, and maximum dose allowed of PRN) and 
the total dose taken. Patients were further asked if they took any of the adjuvant analge-
sics gabapentin, carbamazepine or amitriptyline.
Quality of analgesic treatment
The PMI relates the patients’ worst pain intensity (categorized as 1, mild (1-3); 2, mod-
erate (4-7); or 3, severe (8-10)) to the most potent pain medication prescribed by the 
clinician (0, no analgesics; 1, WHO Step 1; 2, WHO Step 2; and 3, WHO Step 3 or 4). It is 
calculated by subtracting the pain level from the analgesic level7. Negative PMI scores 
are considered to be indicators of inadequate pain management, while scores of 0 or 
higher are considered ‘adequate’. 
Adherence
Adherence rates for the past 24 hours were calculated for ATC regimens (i.e., dose taken 
divided by dose prescribed, multiplied by 100) for all classes of medication26. Inadequate 
adherence was defi ned as an adherence rate of <100%. 
Contribution of Quality of Prescription and Adherence
For the evaluation of the contribution of inadequate prescriptions vs. inadequate adher-
ence, we compared adherence rates to the PMI data. 
Statistical analysis
Proportions are reported with their 95% confi dence intervals (95% CIs) as appropriate. 
Diff erences in proportions were tested with the Chi-squared test or Fisher‘s exact test 
as appropriate. Means are reported with their standard deviation (SD), medians with 
their range. Diff erences in means were tested with Student t-test. Reported P-values are 
two-tailed and were considered signifi cant at P < 0.05 level. 
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RESULTS
Prevalence and Intensity of Pain, and Breakthrough Pain
A total of 246 of 915 patients (27%, 95% CI: 24%-30%) had pain or used analgesics 
in the past week. Table 1 shows the prevalence of pain among categories defi ned by 
sociodemographic or medical variables. Pain was seen more often in female patients, in 
patients with poor performance status, in patients with distant metastases, in patients 
who had received antitumor treatment within the previous six weeks, and among those 
treated, in patients who were treated with a palliative intent. Furthermore, pain was not 
distributed equally among cancer types, and was present most frequently among breast 
cancer patients. The mean pain intensities were 3.8 + 2.4 (present pain), 6.4 + 2.4 (worst 
pain), and 4.1 + 2.2 (average pain). One hundred thirty-three patients (54%) reported a 
worst pain score of 7 or above, while 34 (14%) reported an average pain score of 7 or 
above in the last 24 hours (Figure 1). Pain interfered ‘quite a bit’ or ‘very much’ with the 
patients’ daily activities (51%), work (47%), and sleep (41%) (Figure 2). 
Table 1 Sociodemographic and Medical Variables (n=915)
N (%) with pain P
Male (n=416) 98 (24) 0.04
Female (n=499) 148 (30)
ECOG 0-1 (n=758) 165 (22) <0.001
ECOG 2-4 (n=119) 57 (48)
NED (n=344) 57 (17) <0.001
Locoregional (n=328) 92 (28)
Distant metastases (n=243) 97 (40)
With antitumor therapy (n=403) 145 (36) <0.001
Without antitumor therapy (n=512) 101 (20)
With curative intent of therapy (n=213) 58 (27) <0.001
With palliative intent of therapy (n=190) 87 (46)
Breast cancer (n=286) 91 (31) 0.02
Head and neck cancer (n=155) 41 (26)
Hematological malignancies (n=120) 21 (18)
Urological cancer (n=107) 22 (21)
Other cancer (n=247) 71 (29)
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Breakthrough pain was present in 57 patients (45%, 95% CI: 36%-54%) of the 126 
patients with ATC analgesics. The mean average pain of these patients was 4.5 ± 1.5, and 
the mean maximum pain was 7.8 ± 0.9. 
0
10
20
30
40
50
60
70
0 1-4 5-6 7-10
BPI Pain Scores
Figure 1. BPI pain scores. Percentage of patients reporting pain scores in the BPI. Worst pain = black bars; 
average pain = dark gray bars; least pain = white bars; current pain = light gray bars.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
activity (n=245)
mood (n=245)
walking (n=245)
work (n=241)
relations (n=239)
sleep (n=244)
enjoyment (n=243)
% of patients
Figure 2. Interference of pain with various activities of daily living. Very much interference = black; quite a 
bit interference = dark gray; a little interference = light gray; no interference at all = white.
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Analgesics
A total of 180 of 246 (73%, 95% CI: 68%-79%) patients with pain had been prescribed 
analgesics (Table 2). Only 70% of patients with a prescription had ATC analgesics, and 
58% had access to PRN analgesics for breakthrough pain. The median oral equianal-
getic morphine dose of patients taking WHO Step 2 or Step 3 opioids (including one 
patient who had parenteral opioids) was 60 mg/day (range: 7-360 mg). Of the patients 
with WHO Step 1 and Step 2 prescriptions, the analgesics were prescribed ATC in 61%, 
whereas WHO Step 3 analgesics were prescribed ATC in 94% of patients (Table 2). The 
adjuvant analgesics were prescribed infrequently: gabapentin in 3%, carbamazepine in 
1% and amitriptyline in 3% of patients. 
Table 2 Analgesic prescriptions ‘by the clock’ and ‘by the ladder’
ATC
N (%)
PRN
N (%)
ATC and PRN
N (%)
N
WHO 1 80 (51) 60 (38) 17 (11) 157
WHO 2 29 (58) 20 (40) 1 (2) 50
WHO 3 22 (47) 3 (6) 22 (47) 47
WHO 4 0 1 (100) 0 1
Any analgesic 75 (42) 54 (30) 51 (28) 180
No analgesics 66
ATC = around-the-clock; PRN = as needed
Quality of Pain Management
Poor (worst pain score 7 – 10) or very poor (average pain score 7 – 10) pain control was 
seen across all analgesic categories, suggesting that patients were receiving inadequate 
opioid therapy (Figure 3)33. The PMI was negative in 158 of 244 patients (65%, 95% CI: 
59%-71%), indicating inadequate pain management (Figure 4). 
Adherence
The proportions of patients adherent to ATC analgesics varied from 59% (tramadol), to 
78% (NSAIDs) and 91% (Step 3 opioids), but proportions were not signifi cantly diff erent 
due to small numbers. A total of 125 patients had a prescription for ATC analgesics and 
were evaluable for comparison of PMI and adherence (Figure 5). By PMI, 68 patients (55%) 
were adequately managed and 57 (46%) were not. Overall, 91 patients (73%) adhered to 
their analgesic prescription, while 34 (27%) were nonadherent. Of the 57 patients with 
inadequately managed pain, 19 (33%) were nonadherent to their analgesic medication. 
Of the 57 patients with breakthrough pain and a prescription for ATC medication, 16 
(28%) were nonadherent. Of the 23 patients with breakthrough pain and a PRN prescrip-
tion, only 4 (17%) actually took ≥ 80% of the PRN medication allowed.
Wendy Oldenmenger bw.indd   22 08-11-11   10:32
Cancer pain treatment in the Netherlands 23
DISCUSSION
Studies to date show a wide variation in the reported prevalence of cancer pain. In the 
present study, 27% of outpatients treated in a cancer center reported to have pain, 
which is lower than found in previous prospective studies in outpatients. Among out-
patients at various stages of cancer, the prevalence varied from 40% to 61%14,34-36. The 
prevalence of cancer pain in outpatients with advanced cancer varied in prospective 
0
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45
none non-opioids weak analgesics strong analgesics
Type of medication
Figure 3. Percentage of patients receiving no pain medications, nonopioid analgesics, weak opioids, or 
strong opioids. BPI average pain score 0 - 4, n=136 (good pain control) = white bars; BPI worst pain score 
7 - 10, n=133 (poor pain control) = gray bars; BPI average pain score 7 - 10, n=34 (very poor pain control) = 
black bars. 
0%
5%
10%
15%
20%
25%
30%
35%
-3 -2 -1 0 1 2 3
Pain Management Index
Figure 4. Percentage of patients by Pain Management Index (PMI). 
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studies between 67% and 78%, compared to 40% in our series7,37-38. The diff erent clinical 
settings may explain these diff erences. 
In the present study, 45% of patients with a prescription for ATC analgesics had break-
through pain in the past week. The incidence of breakthrough pain varies widely from 
40% to more than 90% of patients, depending on the defi nitions used and the clinical 
setting39-43. Less restrictive criteria have been used both for the defi nition of pain and for 
the analgesics used. Alternative defi nitions of breakthrough pain included any transient 
exacerbation of pain that could be distinguished from baseline pain, or any pain that 
varied with time, including episodes of pain on a pain-free background40,43. In several 
studies, a fi xed schedule of opioids was a prerequisite for the diagnosis1,23. However, as 
in previous studies, we accepted any medication taken on a fi xed schedule22. We used 
a stricter defi nition of pain and, as may be expected, found a lower prevalence (45% 
compared to 63%)22. 
Seventy-three percent of patients with pain were treated with analgesics. Most (87%) 
of them had WHO Step 1 analgesics, approximately 25% had WHO Step 2 analgesics, and 
25% had WHO Step 3 analgesics. 
A negative PMI was seen in 65% of patients with pain. Since the PMI is considered a 
conservative estimate, this result is disappointing. Most would consider a low dose of 
WHO Step 3 opioids or a PRN opioid schedule inadequate for patients who experience 
severe background pain, but both examples would be considered adequate according 
to the PMI. One might hypothesize that the pain could be neuropathic in a large amount 
of patients, and since the PMI does not consider adjuvant analgesics, it would not refl ect 
the quality of treatment in such patients. However, since fewer than 5% of our patients 
were treated as such, this hypothesis does not hold. A negative score on the PMI was 
seen in 13%-79% of patients in previous studies (Table 3)7-21. There are no prior data 
available for Dutch outpatients. 
Self-reported adherence is fraught with diffi  culties, but it has been used in all previous 
studies on adherence among cancer patients25-26,44-46. We found that the proportions of 
patients adherent to ATC analgesics varied from 59% (tramadol) to 91% (Step 3 opioids). 
In earlier reports, patients took an average of 80%-89% of their ATC opioids25-26,44-46. 
43%
12%
30%
15%
Figure 5. Relative contribution of prescription (PMI) and adherence to effi  cacy of pain management 
(n=125). Positive PMI and adherent (43%) = black piece; positive PMI and non-adherent (12%) = light gray; 
negative PMI and adherent (30%) = gray; negative PMI and non-adherent (15%) = white. 
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In 125 patients with a prescription for ATC analgesics, we estimated the contribution 
of patient adherence to pain management. Sixty-eight (54%) of these 125 patients were 
adequately managed, as indicated by a positive PMI. However, of the 57 (46%) with a 
negative PMI, 33% were nonadherent despite the presence of pain. Of the 23 patients 
with breakthrough pain and a PRN prescription, only four (17%) actually took ≥ 80% 
of the PRN medication allowed. These fi ndings indicate that improvement of patient 
adherence may contribute to better pain management.
There are several limitations that should be considered in interpreting the results of 
this study. First, information about analgesic prescriptions was based on patients’ report 
and may not have been accurate. To overcome this problem, patients who could not 
reproduce their prescriptions had follow-up phone calls. Second, recently, sophisticated 
methods of measuring adherence have become available, e.g., a medication event moni-
toring system (MEMS) in which a microprocessor in a special pill-bottle cap records the 
number of times that the pill bottle is opened. MEMS was not used since it is expensive, 
especially when evaluating a complex analgesic regimen, but MEMS will be used in a 
longitudinal study in our center. Third, the cutoff  for adherence in the present study was 
100%, while the traditional cutoff  for adherence derived from studies on hypertension 
Table 3 Adequacy of treatment (Cleeland Pain Management Index)
Country n
% worst
PI > 4
mean 
worst PI
% strong 
opioids
% 
inadequate
treatment 95% CI Reference
Germany 905 NS NS 71% 13% 11-15% Sabatowski12
Japan 121 NS 4.9 NS 27% 20-36% Uki16
USA 139 66% 5.7 39% 29% 22-37% Wells17
South Africa 426 74% 5.7 36% 30% 26-35% Beck13
Korea 508 47% NS 25% 41% 37-45% Hyun14
USA 597 62% NS NS 42% 38-46% Cleeland7
Italy 117 NS NS NS 43% 34-52% Cascinu20
Netherlands 313 91% 7.7 36% 49% 44-55% de Wit49
France 270 69% NS 26% 51% 45-57% Larue8
Korea 464 64% 5.5 NS 53% 48-57% Yun19
USA 281 67% 5.7 37% 65% 59-70% Cleeland15
China 147 70% NS 27% 67% 59-74% Wang10
Taiwan 113 65% 5.7 NS 69% 60-77% Ger18
Greece 220 85% 7.4 10% 75% 69-80% Mystakidou11
Israel 218 80% NS NS 75% 69-80% Shvartzman21
India 200 84% 7.4 NS 79% 73-84% Saxena9
Netherlands 244 81% 6.4 26% 65% 59-71% present study
NS= not stated; PI= pain intensity 
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was 80%47. For HIV-1 infection, it has been demonstrated that > 95% adherence is neces-
sary for successful treatment48. It is not clear which cutoff  should be taken for cancer 
pain. However, in our study there was no diff erence between patients > 80% adherent 
and patients 100% adherent.
In summary, 27% of cancer outpatients were found to have pain, and 45% of patients 
on ATC analgesics had breakthrough pain. Sixty-fi ve percent of patients were under-
treated, as indicated by a negative PMI. About one-third of patients with a negative 
PMI did not adhere to their analgesic prescription. Apparently, both poor analgesic 
prescriptions and poor adherence contribute to ineff ective cancer pain treatment. We 
have begun a longitudinal study where quality of pain treatment will be monitored by 
pain experts, and adherence will be measured by MEMS. 
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ABSTRACT 
The aim of this paper is to identify the major barriers hindering adequate pain manage-
ment and critically review interventions aiming to overcome them. We searched rel-
evant literature on PubMed published between January 1986 and April 2007. The most 
frequently mentioned barriers for both patients and professionals were knowledge 
defi cits, inadequate pain assessment and misconceptions regarding pain. Four inter-
ventions were identifi ed: patient education, professional education, pain assessment 
and pain consultation. These interventions were never combined in multidisciplinary 
study protocols. Most RCTs included small groups of patients and reported no power 
analysis. Studies on professional education and pain assessment did not evaluate pa-
tients’ outcomes. In 5 of 11 RCTs on patient education, pain intensity decreased statisti-
cally signifi cantly. In two RCTs on pain consultation, patients’ pain decreased statistically 
signifi cantly, although the adequacy of pain treatment did not change. In conclusion, 
international guidelines on multidisciplinary interventions in pain management are 
partly substantiated by clinical trials.
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INTRODUCTION
Pain is one of the most frequent and distressing symptoms in cancer. Pain is present in 
36 - 61% of patients depending on cancer type, stage of disease and patient setting, e.g. 
in- or outpatients1-3. Of patients with advanced cancer 64% experience pain4. Manage-
ment of cancer pain is considered to be complex. In 1986, the World Health Organization 
(WHO) published the analgesic ladder5. The WHO analgesic ladder categorizes analge-
sics into three steps which, depending on the pain intensity, progress from non-opioid 
analgesics to weak opioids and then to strong opioids. Analgesics should be prescribed 
‘around-the-clock’ (ATC) for continuous pain and ‘as needed’ (PRN) for breakthrough 
pain5. The WHO analgesic ladder has been generally accepted as the foundation of 
cancer pain treatment. The fact remains, however, that despite the existing guidelines 
and knowledge about pain and pain management, cancer pain relief is still inadequate6. 
Cleeland et al. developed the ‘Pain Management Index’ (PMI), a tool to assess the 
congruence between severity of pain and medication prescribed7. The PMI relates the 
patients’ worst pain intensity (categorized as none, mild, moderate or severe) to the most 
potent analgesic prescribed (no analgesics; nonopioid analgesics; weak opioids; strong 
opioids). It is calculated by subtracting the worst pain from the most potent analgesic 
prescribed. Negative PMI scores are considered to indicate suboptimal medication pre-
scription and scores of zero or greater are considered indicating acceptable analgesic 
potency7. According to the PMI, 43% of patients, outpatients as well as inpatients, are 
treated inadequately8. 
However, although almost half of the patients are treated inadequately8, it has been 
proposed that eff ective treatment of pain should be feasible for 70-90% of oncology pa-
tients6. Numerous barriers have been documented that prevent patients from receiving 
eff ective pain treatment and avert physicians from providing adequate pain manage-
ment. The fi rst aim of this paper is to identify the major barriers hindering adequate 
pain management, patient – related barriers as well as professional – related barriers. 
The second aim is to critically review RCTs on interventions aiming to overcome these 
barriers with respect to the methodological quality of these studies and the eff ect on 
clinically relevant outcome measurements.
METHODS
Relevant literature published in English was searched on PubMed from 1986 to April 
2007. The search was limited to adults, cancer and humans. The terms ‘pain manage-
ment’ and ‘barrier* or concern*’ were used as keywords to identify relevant titles and 
abstracts. We restricted the search to patients and health care providers. We found 
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121 articles of which 40 were relevant. Additionally we conducted a search using the 
medical subject headings terms of ‘pain management’ and ‘health knowledge, attitudes, 
practice’ (n=80), which produced twelve supplementary articles. The reference list of 
each relevant article and the senior author’s personal library was checked to retrieve 
additional relevant publications, which were not identifi ed by means of the computer-
ized search (n=18) (Figure 1). For the study of interventions to overcome the published 
barriers we selected randomized clinical trials (RCTs). The methodological quality of the 
RCTs was assessed using the criteria of Van Tulder et al9. We added a criterion to what 
extent the power analysis was reported. The main outcome measurements used were 
patients’ pain intensity (average pain, worst pain and current pain), patients’ or profes-
sionals’ knowledge or barriers, adherence to analgesics and adequacy of pain treatment, 
measured with the pain management index (PMI)7. To give an indication of the eff ect of 
the intervention studied in the RCT on pain, we calculated the diff erence in the decrease 
of pain intensity, with respect to baseline, between the intervention and the control 
group. A clinically relevant eff ect was defi ned as a diff erence in the reduction of pain 
intensity with 30% or ≥ 2 points on a 0-10 scale10. If insuffi  cient data on pain intensities 
were reported in the articles (e.g. only in graphs), we tried to contact the fi rst author in 
order to gain access to the source data. All data on the statistical signifi cances, reported 
in this review, were retrieved from the original papers (Table 3).
Potentially relevant studies 
identified and screened for 
retrieval (n=121)
Title or abstract indicated 
that the study did not meet 
inclusion criteria (n=81)
Second search using MeSH 
terms (n=80)
Additional search of references
(n=18)
Studies meet inclusion criteria
(n=70)
Title or abstract indicated 
that the study did not meet 
inclusion criteria (n=68)
Figure 1. Flow chart.
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RESULTS
1. Patient-related barriers
Patients often impede their own treatment due to misconceptions about analgesics and 
their side eff ects, non-adherence to treatment regimens, and poor communication of 
their pain and their concerns about pain to health care providers11-12. In 1993, Ward et 
al. designed a 27-item questionnaire containing eight barriers, the Barriers Question-
naire (BQ)13. The BQ is a self-report instrument designed to measure the extent to which 
patients have barriers refl ecting two general factors: beliefs that hinder communication 
about pain and beliefs and attitudes that may interfere with the use of analgesics. In 
Table 1, an overview of 10 studies is given, in which the BQ was used. 
The sample size varied between the studies, ranging from 35 to 270 patients. Four 
studies included more than 100 patients. In two studies, no BQ total score could be 
determined. Patients were most concerned about addiction, side-eff ects of analgesics, 
and that increased pain means progression of disease13-22. 
Several studies using the BQ examined to what extent patients’ barriers infl uenced 
pain management. These studies described that the patients who hesitated to report 
pain indeed had signifi cantly higher BQ total scores as compared with the patients who 
did not hesitate15,20,23-24. Patients with a negative PMI, which indicates suboptimal use 
of analgesics7, had signifi cantly higher BQ total scores than those patients who were 
adequately medicated13,15-16,18,21,24-27. Patients who hesitated to use analgesics had signifi -
cantly higher BQ total scores as well15-17. 
Fourteen studies were published about adherence to analgesics by cancer patients. 
Adherence rates varied from 20% to 95%25,28-40. Two of these studies examined the rela-
tion between adherence and patients’ barriers. According to the study of Thomason 
et al., patients taking their medications only as needed (48%) had more barriers25. The 
study of Lai et al. showed that the stronger patients believed that they could control 
their pain themselves, the less likely they were to adhere to the prescribed regime. In 
addition, the stronger they believed that medication was necessary for their pain, the 
more likely they adhered to their analgesic regime34.
2. Intervention to reduce patient-related barriers: patient education
Patient education has been suggested as a method to overcome patients’ barriers. Vari-
ous Pain Education Programmes (PEPs) were developed to improve patients’ knowledge 
and to stimulate them to participate actively in their own pain treatment. We found 11 
RCTs evaluating PEP. The programmes varied greatly in type, content and duration. The 
educational interventions ranged in complexity from a single session (approximately 
20 min)41 to an academic detailing session tailored to patients’ prior knowledge in 
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combination with written instructions, pillbox and three follow-up phone calls and two 
follow-up home visits42 (Tables 2 and 3).
The sample size varied widely between the studies. Four studies included >100 pa-
tients while four other studies included <60 patients (Table 2). Two studies reported their 
power analysis. Two other studies did not describe their dropout rate, in the remaining 
studies the dropout rate was acceptable (<25%). Only four studies clearly described the 
method used to randomize their patients. The study duration diff ered from 5 days to 8 
weeks. Five studies measured a long-term eff ect (> 4 weeks) of the intervention (Table 3). 
All studies used patients’ pain intensity as the main outcome measurement. One study 
did not specify what type of pain intensity was measured39,43; and three other studies 
measured one type of pain intensity35,41,44. The seven remaining studies measured sev-
eral types of pain intensity (e.g. average pain, current pain and worst pain) according to 
Table 2. Methodological Quality Assessment of Pain Intervention RCTs.
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the method sections of the respective papers39,42,45-49. However, three of these studies 
reported only one type of pain intensity39,45-46, in one of them not further specifi ed48. 
The pain intensities that were measured but not reported in the original paper were 
described as ‘not reported’ in Table 3. 
In one study, we could not calculate the eff ect of PEP on pain intensity because of 
insuffi  cient information35. Although fi ve studies described statistically signifi cant diff er-
ences in the decrease of pain, with respect to baseline, between the intervention and 
control group41-42,46-47,50, in only two of them42,47 the diff erences in the decrease of pain 
could be classifi ed as clinically relevant (reduction of pain intensity with ≥ 30% or ≥ 2 
points on an 11-point scale)10. However, one of these studies had a small sample size 
(n=30), no power analysis performed and a follow-up of 5 days47. In three studies, the 
control group reported less pain at the end of the study, although this was not statisti-
cally signifi cant43,45,48.
Ten studies evaluated patients’ knowledge or barriers (Table 3). Eight of them reported 
a statistically signifi cant improvement in knowledge about cancer pain and its manage-
ment in the intervention group compared to the control group35,39,43-44,46-47,49,51, while two 
studies found no diff erences41,48. Three studies measured this knowledge at long-term (> 
4 weeks) follow up44,48,51. Only one study reported a statistically signifi cant improvement 
in the intervention group at long-term follow-up42. 
Three out of six studies reported a statistically signifi cant improvement on patients’ 
adherence to analgesics in the intervention group compared to the control group. 
3. Professional - related barriers
Several studies have found professional-related barriers that may hamper therapeutic 
strategies. Most of these data were collected by surveys. In these surveys, the investiga-
tors used a list of possible barriers to eff ective pain management developed by the Pain 
Research Group at the University of Wisconsin, which included factors related to health 
care system, professionals and patients. In Table 4, an overview of the barriers that were 
reported most frequently by physicians and nurses is given. 
Physicians and nurses reported the following barriers most frequently: (a) inadequate 
assessment of pain and pain management52-60, (b) patients’ reluctance to report their 
pain or to give a pain score13,52,54,56-60 and (c) inadequate knowledge of pain management 
of professionals (both physicians and nurses)52-60. 
Other studies, not mentioned in Table 4, also supported the notion that professionals 
may have inadequate knowledge. These studies used self-constructed questionnaires 
to measure professionals’ knowledge on the topics: pain assessment, principles of 
pain management and management of side-eff ects61-69. Between 34% and 86% of the 
professionals overestimated the likelihood of addiction or tolerance52,55,59,65,70 and ap-
proximately 35% of the physicians believed that morphine has an upper limit62. 
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4. Interventions directed at professionals to improve pain management
Our review identifi ed three interventions directed at professionals that intended to im-
prove the management of cancer pain, namely professional education, pain assessment 
and pain consultation or protocol. In total, six RCTs were identifi ed concerning these 
interventions (Tables 2 and 5). The sample size varied from 60 to 320 respondents (Table 
2). One of the six studies reported their power analysis. One study did not describe the 
drop out rate. Four studies described clearly how they randomized their respondents.
For the fi rst intervention, to increase professionals’ knowledge through education, we 
found two RCTs. The educational interventions targeted nursing staff  in both studies 
(Tables 2 and 5). The fi rst RCT by Camp-Sorell et al.71 reported none of the outcome 
measurements that we considered relevant (Table 5). In the study of Vallerand and 
colleagues72, the intervention showed no signifi cant diff erences in perceived nurses’ 
barriers or perception of control over patients’ pain, but signifi cantly increased nurses’ 
knowledge72. 
Two RCTs evaluated the eff ect of pain assessment73-74. In the RCT conducted by Kravitz 
et al.73, research staff  assessed pain intensity in all patients. However, only of the patients 
randomly assigned to the intervention group, they recorded the pain scores on bedside 
charts without active communication with the professionals. Health care providers were 
not actively involved in the study. Current and worst pain intensity was measured in every 
patient, but these data were not reported. The intervention did not result in improved 
pain control73. In the study conducted by Trowbridge et al.74 all patients completed pain 
assessments (e.g. average and worst pain intensity; pain treatment regimen and degree 
of pain relief ). Only the clinical charts of the intervention group contained a summary 
of the pain scales. Oncologists were instructed to review the summary sheet prior to an 
evaluation. Data on the pain intensities were not reported in the article, but the authors 
suggest that the study resulted in a signifi cant decrease in the proportion of patients 
with pain in the intervention group (from 70% to 55%). However, the proportion of 
patients with pain in the control group was not reported. In addition, they reported no 
diff erences between the intervention and control group in the percentages of patients 
with negative PMI scores (35% versus 38%)74. 
The third intervention was the implementation of a pain consultation32 or pain 
protocol75 to improve pain management (Tables 2 and 5). In the study of Du Pen et al., 
a specialized physician evaluated patients’ pain following the Agency for Health Care 
Policy and Research (AHCPR) guidelines. With respect to the outcome measurements we 
defi ned, they found no statistically signifi cant diff erence for worst pain or patient adher-
ence between the intervention and control group (Table 5). In this study, they reported 
a statistically signifi cant reduction in ‘usual’ pain intensity in the intervention group 
compared to the control group (not in table). This reduction was clinically relevant after 
3 months (approximately 35%). Cleeland et al.75 introduced in their RCT a pain manage-
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ment protocol in the intervention centers, randomizing by center. Although they used 
the BPI, they only reported on the intensities of worst pain, the primary end-point of 
the study, and average pain. Worst pain decreased statistically signifi cantly in the inter-
vention group, although not clinically relevant. In the control group, a non-signifi cant 
reduction was reported (Table 5). A between-groups analysis was not described. The 
study was terminated early because of slow accrual. Since the study was underpowered 
they examined diff erences in proportions of responders, defi ned as patients whose 
worst pain scores changed from moderate or severe to none or mild, rather than mean 
levels of worst pain scores. The proportions of patients responding to pain treatments 
were 48% (protocol) versus 15% after 15 days (p=0.008) and 52% versus 19% after 29 
days (p=0.045). This study showed no diff erences in PMI75. 
DISCUSSION
According to the multidisciplinary task force of the American Pain Society (APS), the 
adequacy of cancer pain management will only improve when a multidisciplinary and 
multilevel approach will be chosen. All cancer patients should be routinely screened for 
pain during their visit in the clinic and their pain intensity should be documented and 
frequently reassessed. When patients are in pain, this should be adequately treated with 
a multidisciplinary evidence-based pain protocol. As a part of this, patients and their 
relatives should be educated regarding pain and analgesics76. 
Although, internationally, this approach is considered the only way to eff ectively 
improve daily cancer pain management, it is not substantiated in the studies here re-
ported. Our review of the literature identifi ed the most important patient-related as well 
as professional-related barriers hampering patients’ pain treatment and also identifi ed 
the studied interventions to overcome these barriers. Unfortunately, we were incapable 
to identify interventions that unequivocally demonstrated clinically relevant improve-
ments in patients’ pain using the outcome measurements and criteria we selected for 
this systematic review. Of note, the results of the studies on patient education could 
even be fl attered because some of the studies did not report all measured pain intensi-
ties (Table 3). The negative fi ndings from the studies may be due to several factors. 
The fi rst factor is the quality of the design and reporting the studies. Many studies 
used small groups of patients and did not substantiate the sample size with a power 
analysis. Furthermore, most studies on professional education and pain assessment did 
not study or report the eff ect of the intervention on patients’ pain. Although pain is 
a major problem in patients with cancer, internationally there is no consensus on the 
most important end-points for pain research, for example which pain intensity is most 
relevant (e.g. current, average or worst pain intensity). According to the recommenda-
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tions formulated by Dworkin et al. pain intensity is one of the core end-points in clinical 
pain trials77. However, in the various studies in which pain intensity was used as the main 
outcome measurement, e.g. studies on patient education and pain consultation or pain 
protocol, diff erent types of pain intensity were measured, making an overall analysis 
impossible. In this review, we chose to report clinically relevant results (reduction of 
pain intensity with ≥ 30% or ≥ 2 points on an 11-point scale) according to Farrell et al.10. 
Other possibilities as ‘numbers needed to treat’ would have been potential alternatives, 
but in this review it is not possible because the included RCTs did not report these data. 
Another explanation for the negative fi ndings in the reviewed RCTs is that most of 
these trials studied a monodisciplinary intervention without standardizing and optimiz-
ing the practice of other disciplines, especially the medical one. For example, when 
studying the eff ect of patient education, in all RCTs it was only described as a nursing 
intervention, without taking the role of physicians into account. Adequate medical 
treatment may be pivotal before patient education becomes eff ective45. 
We think that adequate medical treatment is a prerequisite for other interventions. 
As reported in the survey of Enting et al.28, insuffi  cient awareness of cancer pain, in-
adequate analgesic prescription and non-adherence contribute to inadequate cancer 
pain treatment. In this study, 27% of the outpatients treated in a cancer clinic reported 
to have pain. Sixty-fi ve percent of these patients were undertreated, as indicated by a 
negative PMI. Besides this, 27% declared to be non-adherent28. These data indicate that 
most patients will benefi t from more eff ective analgesic prescription besides education 
to improve adherence to the treatment. Indeed, in our review of the literature the two 
studies on optimizing medical treatment, by pain consult or the introduction of a pain 
protocol, both found a statistically signifi cant eff ect on pain intensity. 
In conclusion, over the years professionals as well as patients still report many barriers 
regarding pain and pain management. The most frequent barriers for both groups are 
inadequate pain assessment and inadequate knowledge and misconceptions regarding 
pain management. Our review indicates that despite all the studies and guidelines, there 
is no convincing study that showed a multidisciplinary intervention to improve cancer-
related pain treatment. Future research should focus on a multilevel approach: structural 
identifi cation of cancer-related pain, implementation of a multidisciplinary protocol to 
improve the quality of pain treatment and education of patients and their relatives to 
enhance their involvement in the pain treatment. Furthermore, international consensus 
about the primary outcome measurement in pain research is urgently needed. 
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ABSTRACT
Adherence to analgesics in cancer patients has scarcely been studied. In this study, the 
Medication Event Monitoring System (MEMS) and medication diaries were compared 
with respect to feasibility and adherence measurements. Forty-six outpatients with 
nociceptive pain caused by cancer were asked to use MEMS for their analgesics and 
to record their medication usage in a diary for four weeks. Seventy-nine percent of the 
patients used MEMS for the full four-week period; 70% did so for the diary. The majority 
of patients were satisfi ed with both MEMS and diary. Adherence data assessed by MEMS 
and diary were comparable. Patients used the amount of analgesics adequately (taking 
adherence: 87%) but took them irregularly (timing adherence: 53%). Subgroup analyses 
in patients using single and multiple analgesic regimens confi rmed the comparable suit-
ability of both methods. MEMS and a medication diary are equally useful for analgesic 
adherence measurement in cancer patients with pain.
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INTRODUCTION
In 2003, the World Health Organization (WHO) adherence project made the following 
defi nition of patients’ adherence: “the extent to which a person’s behavior, taking medi-
cation, following a diet, and/ or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider”1. Of all treatment recommendations, 
pharmaceutical interventions are the easiest interventions to which patients can ad-
here1. Patients are expected to take their medication as prescribed. However, patients’ 
adherence to long-term therapies averages merely 50% in developed countries; in 
developing countries, the rates are even lower2. 
Medication adherence has been extensively studied in patients with various diseases 
or conditions3-10. In chronic diseases, both direct and indirect methods have been used. 
Direct methods provide proof of ingestion of the studied drug by measuring the drug or 
its metabolite in plasma, urine or hair. However, measured drug concentrations do not 
necessarily correlate with overall adherence10-11. Indirect methods include self-report, 
prescription refi lls based on pharmacy records, pill counts, and electronic monitoring. 
Of these methods, the most frequently used assessment tool is self-report, for example, 
by interview, questionnaires and diaries. Advantages of self-report include the low costs, 
and the fast and easy documentation and collection of data. Furthermore, diaries can 
provide information on adherence to multiple medications used in combination. Espe-
cially for research purposes, self-report also can provide insight into patients’ barriers 
to medication intake6,12. Self-report, however, is limited by patient memory. Moreover, 
the use of diaries over time is variable, and patients tend to complete them retrospec-
tively6,11-13.
Electronic monitoring of medication intake has been introduced during the last de-
cade, in particular by using the Medication Event Monitoring System (MEMS)14-15. MEMS 
is available in various packages: vial-type containers; eye drop dispensers; inhalers 
time-stamp; and blister packages. MEMS vials are most frequently used. A MEMS vial 
is a standard medication vial with a cap containing a microprocessor that accurately 
records time and date of each opening and closing. Information regarding medication 
intake can easily be displayed and used for statistical analysis using specially designed 
software. 
MEMS allows long-term monitoring with detailed information about patterns of 
medication use. However, the tablets have to be removed from the original container or 
blister, and medication changes within a study period can yield inaccuracies12,14,16. Simi-
lar to all indirect adherence methods, MEMS does not confi rm ingestion of medication11.
Several studies in various nonmalignant diseases compared MEMS with self-report for 
medication adherence measurement. In all these studies, self-report assessments over-
estimated adherence in comparison to MEMS3,5,17-20. An average of 30% of diary entries 
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were in error compared with MEMS data17. These studies concluded that MEMS was the 
most accurate adherence measurement instrument available14,17,20. 
Although adherence has been studied in various chronic diseases, adherence to 
analgesics in cancer patients has not been studied extensively. Pain occurs in 30%-50% 
of cancer patients in the early stages of disease, and in 70%-80% in advanced stages21-24. 
Lack of adherence to pain medication is one of the reasons that patients do not achieve 
adequate pain control25. From 1981 to 2005, 14 studies were published about adher-
ence to analgesics by cancer patients. In all these studies, adherence was measured by 
self-report. In only three studies, investigators used diaries; in the other studies, ques-
tionnaires or interviews were used. Adherence rates varied between 20% - 90%25-38. In 
oncology, patients are often treated with a combination of various opioid and nonopioid 
analgesics. In the studies on electronic monitoring of medication adherence mentioned 
above, MEMS was always used for only one drug. In case of multiple drug use, patients 
were asked to transfer the medication with the most complex prescription into a MEMS 
vial16. Therefore, studies investigating adherence to multiple analgesic regimens, such as 
used in cancer pain, are lacking.
In this study, we determined the feasibility of using MEMS vials in comparison with 
medication diaries in cancer patients with chronic pain on single as well as on multiple 
analgesic regimens. We also compared medication adherence as obtained by MEMS and 
by diary. 
METHODS
Patients 
Between July 1 and December 31, 2004, 46 outpatients of the Erasmus MC Daniel den 
Hoed Cancer Center were included in a prospective study. Patients were eligible if they 
met the following criteria: cancer or treatment-related nociceptive pain; pain duration 
of at least two weeks; a prescription for one or more analgesics for the duration of the 
study with at least one around-the-clock (ATC) regimen; life expectancy of at least three 
months; and able to read and speak Dutch. Patients who used medication-dispensing 
devices, such as pillboxes, and patients who were residing in a nursing home or retire-
ment home, were ineligible. Fifteen patients used one analgesic preparation, 16 patients 
used two, and 15 patients used three diff erent analgesic preparations. 
Procedure
After written informed consent was obtained, patients entered the study for a period 
of four to fi ve weeks, depending on the next appointment at the outpatient clinic. At 
study entry, patients received separate MEMS vials for each monitored analgesic, a 
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medication diary, and prescriptions for analgesics. Patients were subsequently referred 
to their pharmacy to obtain a fresh supply of medication in the MEMS vials. Patients 
were requested to take all their pain medication from the MEMS vials and to open the 
MEMS vials only if they intended to take medication. All patients were informed about 
the nature of MEMS vials. They were also asked to write their medication intake in the 
diary each day. At the end of the study period, an exit interview was planned. Patients 
who returned their diary and MEMS, and answered the exit interview, were considered 
evaluable for feasibility and medication adherence calculation. The Medical Ethics Com-
mittee of the Erasmus Medical Center approved the study. 
Instruments and measurements
So ciodemographic and Medical variables. 
At study entry, sociodemographic variables, including age, gender, and education level, 
were collected by patient interviews. The WHO performance status39 was assessed, and 
patients were asked to rate the severity of their current pain, their ‘worst’ pain, and ‘aver-
age’ pain of the past week using a numeric rating scale40-42. Medical variables, includ-
ing type of cancer, tumor status, anti-tumor therapy, and analgesic prescription, were 
obtained from the medical records.
Adherence measurement. 
Instruments. Electronic adherence measurement was performed using the Medication 
Event Monitoring System version 6 (MEMS®, Aardex, Zug, Switzerland). A separate MEMS 
vial was used for each analgesic preparation. Medication events or openings occurring 
within one hour of a prior vial opening were interpreted as not to represent dosing. For 
adherence measurement per diary, an investigator-constructed medication diary was 
used, with one page allocated for each day. 
Feasibility. Two aspects of feasibility were assessed: the actual use of the instruments 
and patients’ satisfaction. The actual use of MEMS and diary was calculated as: 1) the me-
dian number of days the respective instrument was used, and 2) the number of patients 
who used the instrument during the entire evaluable study period (with a margin of two 
days). Days at which patients were hospitalized were omitted from analysis.
Patients’ satisfaction was assessed in the exit interview with six self-constructed ques-
tions. The questions ‘How satisfi ed are you using MEMS/ medication diary?’ and ‘Did you 
have any problems using MEMS/ medication diary?’ were answered on a 5-points Likert-
type scale. The questions ‘Did you use your diary every day?’ and ‘Did you take your 
medication from MEMS every day?’ were answered by yes or no. In addition, patients 
were given the opportunity to provide comments on MEMS and medication diary.
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Medication adherence. Adherence was assessed for the ATC medication only. Adher-
ence rates according to MEMS and diary were calculated separately. Medication adher-
ence was calculated over the days the respective instrument had actually been used. If 
a patient used multiple ATC analgesic preparations, the separate adherence rates for the 
diff erent preparations were averaged for that patient. Adherence was diff erentiated into 
1) ‘taking adherence’: percentage of total prescribed drugs taken; 2) ‘correct dosing’: the 
percentage of days on which the correct doses were taken; and 3) ‘timing adherence’: 
the percentage of days on which all medication doses were taken within 25% of the 
correct dosing interval, with a maximum of four hours for medication prescribed once 
a day or less8. 
Data analysis
Data were analyzed using the Statistical Package for the Social Science for Windows, ver-
sion 13.0. Descriptive statistics were used to describe patients’ sociodemographic and 
medical characteristics. Diff erences in feasibility between MEMS and diary were analyzed 
with the nonparametric Wilcoxon signed rank test. Diff erences between MEMS and diary 
in adherence were analyzed with parametric tests. A test for repeated measures ANOVA 
was performed to test the diff erences in adherence between MEMS and diary, and one 
versus multiple analgesic prescriptions. MEMS and diaries were included as the “within” 
variable, and the number of analgesics was included as the “between” variable. A P-value 
of < 0.05 (two-tailed) was considered signifi cant. 
RESULTS
Sociodemographic and medical data
The median age of the 46 patients included was 56 years (range 32-77 years); the WHO 
performance status was ≤ 1 in 91% of the patients. Half of the patients received antitu-
mor therapy during the study period. Additional demographic characteristics are sum-
marized in Table 1. Twenty-nine patients were prescribed 32 ATC strong opioids (three 
patients with two diff erent dose preparations): fentanyl patches (n=15), and morphine 
(n=11), oxycodone (n=5) and methadone (n=1) tablets. Seven of these patients also had 
a prescription for opioids ‘as needed’. 
Of the 46 patients, 43 (93%) were evaluable for feasibility and adherence assessment; 
one patient died early, one patient’s MEMS vial was lost, and one patient refused further 
participation in the study one week after inclusion.
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Table 1. Demographic and Disease-Related Characteristics.
  Median (Range) n %
Age (median, range) 56 yr (32-77 yr)
Gender male 20 44
female 26 56
WHO performance status
Grade 0 15 32
Grade 1 27 59
Grade 2 4 9
Cancer status
No evidence of disease 8 17
Locoregional 14 31
Metastatic disease 24 52
Cancer type
Breast 16 35
Lung 11 24
Head and Neck 9 20
Sarcoma 3 7
Gynecological 2 4
Hematological 2 4
Other 3 7
Anti-tumor therapy
Chemotherapy 17 37
Radiotherapy 2 4
Hormonal therapy 3 7
Surgery 1 2
None 24 52
Bisphosphonates 11 24
Pain duration 8 months (1 - 216)
Pain intensity 
 current pain 3.0 (0 - 8)
average pain 5.0 (0 - 10)
worst pain 7.5 (0 - 10)
Analgesics
Nonopioids* 36 78
Weak opioids 8 17
Strong opioids** 29 63
Number of analgesic preparations 
one 15 33
two 16 34
three 15 33
*Nine patients used both acetaminophen and NSAID. 
**Ten patients used two strong opioid preparations.
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Feasibility
Actual use of MEMS and Medication Diary. The median evaluable study period per pa-
tient was 28 days (range 24-34 days). Patients used MEMS and medication diaries both 
for a median duration of 26 days (range for MEMS and diary 9-34 and 0-34, respectively). 
Also, in subgroup analyses for patients using single and multiple analgesic regimens, no 
diff erences were found between the use of MEMS and medication diaries (Table 2). Thir-
ty-four patients (79%) used MEMS during the entire study period, whereas 30 patients 
(70%) did so for the diary. Twenty-seven patients (63%) used both instruments, and six 
patients (14%) used neither MEMS nor diary during the entire study period (Figure 1). 
Table 2. Usage of MEMS and Diary.
Prescription MEMS* Diary* P-value
One analgesic preparation (n=14) 28.5 (22 – 34) 28.5 ( 0 – 34) NS
Multiple analgesic preparations (n=29) 25.5 (9 – 34) 25.5 ( 4 – 34) NS
*usage in days, median (range).
43 evaluable 
patients
27 patients 
MEMS & diary 
feasible
3 patients
MEMS not 
feasible
7 patients
diary not
feasible
6 patients
MEMS & diary
not feasible
Figure 1. Feasibility of the instruments. Feasibility is defi ned as the use of the respective instrument 
during the entire evaluable study period.
Patients’ Satisfaction. Thirty-one patients (72%) indicated that they were moderately 
or very satisfi ed using MEMS, whereas 26 patients (61%) were moderately or very satis-
fi ed with the medication diaries. Most patients had no problems using MEMS (84%) or 
diary (81%). Thirty-fi ve patients (81%) answered that they had used MEMS every day; 
30 patients (70%) said they had fi lled in the diary every day. No statistically signifi cant 
diff erences were found between the evaluations of MEMS and diary. The use of one or 
multiple analgesics did not infl uence patients’ satisfaction.
Patients’ Comments on MEMS and Medication Diary. Eight patients reported that 
they were too ill to fi ll in a diary every day. Nine patients stated that they had fi lled out 
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their diary retrospectively after a few days, and one patient fi lled in the diary several 
days ahead. Seven patients considered MEMS vials easier to use than usual packaging 
(blister pack). Six patients who were prescribed fentanyl patches experienced diffi  culties 
with handling the patches from MEMS vials. Five patients reported that they were more 
adherent to their pain medication because of the use of the medication diary and the 
MEMS vials.
Medication Adherence
The overall adherence rates as assessed by medication diary and MEMS are presented 
in Figure 2. For all three adherence measurements, taking adherence, correct dosing 
and timing adherence, similar results were found for MEMS and diary. Of note, clini-
cally relevant diff erences were found between the diff erent adherence measurements, 
with the highest scores for taking adherence (mean 87% and 85% for MEMS and diary, 
respectively) and the lowest scores for timing adherence (53% and 57%, respectively). 
In Figure 3, adherence rates are presented separately for patients using one or multiple 
analgesic preparations. Using repeated measures ANOVA testing, no signifi cant dif-
ferences between MEMS and diary were found for the three adherence rates and no 
signifi cant interaction between instrument and the number of analgesic preparations. 
Only for correct dosing was the diff erence between one and multiple analgesics statisti-
cally signifi cant [F(1,39)=0.08, P=0.013]. 
timing
adherence diary
timing
adherence
MEMS
correct dosing
diary
correct dosing
MEMS
taking
adherence diary
taking
adherence
MEMS
120,0
100,0
80,0
60,0
40,0
20,0
0,0
Figure 2. Mean (sd) adherence rates for MEMS and diary.
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Adherence was not related to WHO performance status, age, or sex. Adherence did 
not diff er between patients using fentanyl patches and patients using other opioids ATC 
(data not shown). 
DISCUSSION
This study evaluated the feasibility of MEMS in comparison with medication diaries 
for adherence measurement in cancer patients with chronic pain who were receiving 
single-drug or multiple-drug analgesic regimens. In the four-week study period, we 
found no diff erences between MEMS and diaries in feasibility and adherence measure-
ments. Seventy-nine percent of the evaluable patients used MEMS for the entire study 
period, whereas 70% did so for the medication diary. The majority of patients were 
satisfi ed with both MEMS and diary and used both instruments every day. Adherence 
rates measured by MEMS and diary were similar. Subgroup analyses in patients using 
single and multiple analgesics confi rmed the comparable suitability of both methods. 
We conclude that both MEMS and diary are useful and manageable methods for adher-
ence measurement in chronic cancer pain.
In our study, we could not confi rm the results from comparative studies on medication 
adherence measurements performed in nonmalignant diseases. In these studies, elec-
tronically monitored adherence rates consistently ranged between 10% and 30% lower 
than adherence rates as assessed by self-reports16-18,43. We found similar adherence rates 
by MEMS and diary. These results may be explained by the rather high taking adher-
0
10
20
30
40
50
60
70
80
90
100
one analgesic multiple analgesics
Taking adherence MEMS
Taking adherence Diary
Correct dosing MEMS
Correct dosing Diary
Timing adherence MEMS
Timing adherence Diary
Figure 3. Mean adherence rates: one analgesic in comparison to multiple analgesics.
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ence rates (mean 85%-87%) found in our study. Indeed, the measured adherence rates 
were high in comparison with results from earlier studies in cancer pain (30%-91%)25-38. 
The rather frequent use of fentanyl patches for pain management may explain the high 
adherence rates. Furthermore, fi ve patients reported to be more adherent because of 
the use of medication diary as well as MEMS. The fact that nine patients had fi lled out 
their diary retrospectively while mean adherence results were similar for MEMS and 
diary supports the idea that patients had indeed taken their analgesics quite regularly.
Although the study was designed to compare the feasibility of MEMS and diary, the 
study also showed that patients may use their medication with diff erent intervals over 
the day. Patients appear to use the total amount of medication prescribed, but take 
doses at wrong intervals. In future research, it will be interesting to study the relation 
between timing adherence and effi  cacy of pain treatment. 
Limitations of the study may be the sample size, the selection of patients, and the 
duration of the study. We did not perform a power-analysis before start of the study. The 
sample size may be too small to detect small diff erences in feasibility and usefulness 
between MEMS and diary. Many patients included in this study used fentanyl patches, 
which may increase adherence. Furthermore, it is possible that we included a selected 
group of patients. A substantial part of the patients was treated in the pain clinic. These 
patients may be more motivated to adhere to their analgesics. Furthermore, patients’ 
participation might have increased their awareness of medication intake during the 
study. Because we included patients for four weeks, feasibility for using MEMS and diary 
over a longer period remains unknown.
MEMS and diaries have diff erent advantages. In clinical practice, diaries may be pre-
ferred because they are cheap and easy to handle. Patients, however, have to be able to 
remember to complete their diaries accurately and in a timely manner13,16. However, for 
research purposes, data extraction from diaries is time consuming. MEMS allows easy 
analysis of the more detailed patterns of adherence without additional eff ort from the 
patient, because computer programs are available that can read the information from 
the vials. For daily practice, limitations of MEMS are its costs and that it excludes the use 
of common adherence strategies such as pillboxes. 
In conclusion, both MEMS and medication diaries are useful for adherence measure-
ment in cancer patients with pain using single and multiple medication regimens. 
Medication diaries are an inexpensive method and very useful in daily practice. MEMS is 
the appropriate method for research, when more detailed insight in patients’ adherence 
is required. 
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ABSTRACT
Pain Education Programs (PEP) and Pain Consultations (PC) have been studied to over-
come patient-related and professional-related barriers in cancer pain management. 
These interventions were studied separately, not in combination, and half of the studies 
reported a signifi cant improvement in pain. Moreover, most PEP studies did not men-
tion the adequacy of pain treatment. We studied the eff ect of PC combined with PEP 
on pain and interference by pain with daily functioning in comparison to standard care 
(SC). Patients were randomly assigned to SC (n=37) or PC&PEP (n=35). PEP consisted 
of patient-tailored pain education and weekly monitoring of pain and side eff ects. We 
measured overall reduction in pain intensity and daily interference over an 8-week pe-
riod as well as adequacy of pain treatment and adherence. The overall reduction in pain 
intensity and daily interference was signifi cantly greater after randomization to PC&PEP 
than to SC (average pain 31% vs. 20%, P=0.03; current pain 30% vs. 16%, P=0.016; inter-
ference 20% vs. 2.5%, P=0.01). Adequacy of pain management did not diff er between 
the groups. Patients were more adherent to analgesics after randomization to PC&PEP 
than to SC (P=0.03). In conclusion, PC&PEP improves pain, daily interference, and patient 
adherence in oncology outpatients. 
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INTRODUCTION
Pain is one of the most frequent and distressing symptoms in cancer. Pain is present in 
36% to 61% of patients, depending on cancer type, stage of disease and patient setting, 
e.g. inpatient or outpatient departments1-4. Management of cancer pain is considered to 
be complex. Despite the existing guidelines and knowledge about pain and pain man-
agement, almost half of the patients are treated inadequately5. Nevertheless, it has been 
proposed that eff ective pain treatment should be feasible for 70% to 90% of oncology 
patients6. 
Inadequate pain management seems to be caused by professional-related as well as 
patient-related barriers. The most reported barriers in professionals include inadequate 
assessment of pain and inadequate knowledge of pain management7. Patients often 
impede their own treatment due to misconceptions about analgesics and their side 
eff ects, non-adherence to treatment regimens, and poor communication about their 
concerns about pain to health care providers7. 
To improve the adequacy of pain management both professional-related and patient-
related barriers should be reduced. Professional-related barriers could be decreased by 
a pain consultation (PC) or the implementation of a pain protocol8-9. Both Du Pen et al.9 
and Cleeland et al.8 described a reduction in patients’ pain intensity by the introduction 
of a pain protocol. However, they did not discover an improvement in the adequacy 
of pain treatment and patient adherence or a reduction of the interference by pain in 
daily living (daily interference)7-9. To diminish patient-related barriers Pain Education 
Programs (PEPs) were developed to improve patients’ knowledge and to stimulate par-
ticipation in their own pain treatment10-28. PEP decreased patients’ pain intensity in 10 of 
18 studies and improved pain knowledge in 13 of 18 studies. Similar to the studies on 
the introduction of a pain protocol, the adequacy of pain treatment was not improved, 
although this was investigated in only a few studies. Furthermore, PEP did not improve 
adherence to analgesics, nor did it decrease daily interference7,10-28. 
In summary, interventions to diminish professional-related and patient-related bar-
riers in pain treatment found benefi cial eff ects on pain in about half of the studies, 
with no defi nite eff ects on other pain-related outcomes. Furthermore, they were only 
studied separately. Herein, we report the results of a randomized controlled trial (RCT) 
that tested the eff ectiveness of standard care versus standard care supplemented with 
a PC combined with PEP. The primary end point of this study was the overall reduction 
of average pain intensity over the 8-week study period with respect to baseline. The 
predefi ned secondary end points were worst and current pain intensity, interference in 
daily life by pain, pain treatment, adherence and patients’ pain knowledge.
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PATIENTS AND METHODS
Patient population
All patients were treated in the outpatient oncology clinic of the Erasmus University 
Medical Center in Rotterdam. Patients were eligible for inclusion in the study if they 
met the following criteria: (1) 18 years of age or older; (2) confi rmed diagnosis of cancer; 
(3) diagnosis of nociceptive pain related to cancer or cancer therapy by the treating 
physician; (4) average pain intensity in the last week ≥ 4; (5) life expectancy of at least 
three months; (6) able to comprehend, speak, and read Dutch; (7) signed informed 
consent. Patients were excluded in case of residing in a nursing home or retirement 
home, invasive pain treatment (e.g. subcutaneous or intravenous infusion of opioids) or 
radiotherapy planned or received within the last two weeks before inclusion. 
Procedure
The study started in March 2006. Recruitment was conducted through oncology health 
care professionals. The investigators (WHO; PJdR) explained the study, obtained written 
informed consent, and coordinated the study assessments. Patients were stratifi ed for 
treatment with chemotherapy, hormonal therapy or no antitumor treatment. Eligible 
and consenting patients were initially randomly assigned to (1) Standard Care (SC), (2) 
Pain Consult (PC), or (3) Pain Consult combined with Pain Education Program (PC&PEP). 
The randomization was based on a computer-generated randomization procedure with 
a variable block length (1 to 4 repetitions per block). Patients completed a baseline 
assessment before randomization. For patients allocated to one of the intervention 
groups, the intervention was planned within one week after randomization. Study as-
sessments for all groups were conducted 2 weeks (T1), 4 weeks (T2) and 8 weeks (T3) 
after randomization. The questionnaires were sent to the patients by mail. All patients 
fi lled in their questionnaires at home, independently from the health care professionals 
or the investigators. 
In January 2009 the 3-arm study turned out to be not feasible because of slow ac-
crual. Since then, patients were randomized between (1) SC and (3) PC&PEP. The study 
protocol and the amendment were approved by the Institutional Review Board of the 
Erasmus MC. The study was performed according to the ICH-GCP principles. 
Intervention 
Pain Consultation
Patients were evaluated thoroughly with a complete history and physical examination, in-
cluding a pain assessment by a neuro-oncologist. This pain specialist determined whether 
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the cause of the pain was clear; advised on antitumor therapy and optimized symptomatic 
treatment according to national and international cancer pain guidelines29-30, if indicated. 
Pain Education Program
The PEP was developed by De Wit et al.31. The intervention included the use of multiple 
teaching methods, which were provided both in the outpatient clinic and by telephone. 
The pain information (brochure) and instruction was tailored to the needs and the 
abilities of the individual patient. Patients in the PEP group received the intervention 
by a specialized nurse trained in palliative care. The specialized nurse conducted the 
academic detailing session at the outpatient clinic in the fi rst week after inclusion. The 
PEP consists of two components: (1) Enhancing patients’ knowledge about pain and 
pain treatment. Patients were educated about relevant pain topics that were assessed 
by a nurse as insuffi  cient. The verbal instruction was accompanied by a pain brochure. 
(2) Stimulating patients’ help-seeking behavior. An extensive description of PEP can 
be found in the article of the original study31. Until the end of the study at 8 weeks, 
the specialized nurse contacted patients weekly by telephone and reviewed their pain 
intensity scores and opioid-related side eff ects. She contacted the physician if necessary. 
Furthermore, the educational content of the PEP was reinforced if needed.
Outcome assessment
Sociodemographic variables were assessed at study entry. Health-related variables 
included cancer diagnosis; tumor status (no evidence of disease (NED), locally advanced 
disease, or metastatic disease) and antitumor therapy. 
Pain intensity and daily interference were measured on 0-10 numerical rating scales 
with the Brief Pain Inventory (BPI). Pain intensity was measured as current pain and as 
average and worst pain in the last 24 hours. Interference by pain in daily life (daily in-
terference) was assessed by seven items (general activity, mood, walking ability, normal 
work, sleep, relations with other people, and enjoyment of life). A mean interference 
score is computed by taking the average of the 7 items32-33.
Analgesics were categorized to World Health Organization (WHO) step 1 (nonsteroidal 
anti-infl ammatory drugs, acetaminophen), WHO step 2 (tramadol, codeine), WHO step 
3 (morphine, fentanyl patch, oxycodone, and hydromorphone). The various analgesic 
dosages were converted to oral morphine equivalent daily doses (MEDD) (mg/day) 
according to published equi-analgesic dose tables29-30. In addition, the percentage of 
patients with an around-the-clock and as needed (ATC+PRN) analgesic prescription was 
calculated.
The adequacy of analgesic prescription was assessed using the Pain Management 
Index (PMI), which related the worst pain intensity to the most potent analgesic pre-
scribed. It is calculated by subtracting the pain level from the analgesic level. Negative 
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PMI scores were considered to be an indicator of inadequate pain management, whereas 
scores of 0 or higher were considered adequate34. 
Adherence (the percentage of total prescribed drugs taken) for the ATC (ATC) medica-
tion was measured using the Medication Event Monitoring System version 6 (MEMS®, 
Aardex, Zug, Switzerland). A separate MEMS vial was used for each ATC analgesic prepa-
ration35. If a patient used multiple ATC analgesic preparations, the separate adherence 
rates for the diff erent preparations were averaged for that patient. Mean adherence was 
measured in the time intervals: week 1&2; week 3&4; and week 7&8. 
Pain knowledge was assessed using a translated version of the Ferrell Patient Pain 
Questionnaire36. The scores of the eight items were linearly transformed to a 0 to100 
scale (0=lowest knowledge score, 100=highest knowledge score). A mean total score 
was computed for overall pain knowledge at T0 and at T131. 
Data analysis
Defi nitions outcome measures pain and interference
To give a clear representation of the eff ect of our study over the complete period of 
interest (e.g. 8 weeks), we chose for a weighted mean reduction in pain intensity. For 
average, worst and current pain, the overall reduction in pain intensity over the 8-week 
period compared with baseline was calculated using the formula: 
mΔPI = [i=1N (PIi + PIi-1 )( Ti - Ti-1 ) / (2 x (TN – T0) )] – PI0
in which mΔPI was the weighted mean reduction in pain. Pain intensity at time point 
Ti, i = 2, 4 or 8 weeks was reported as PIi and Tn was the last available measurement. The 
overall reduction in interference with daily living was calculated similarly.
Power analysis
Originally the study required a sample size of 156 patients, randomized over the three 
groups, using the assumptions as given in Table 1. The baseline pain intensity was based 
on patients’ pain in a former study in our hospital35. Because of slow accrual, we per-
formed an interim analysis with 54 patients at the end of 2008. According to the interim 
analysis, the most realistic scenario was to continue the study with (1) SC and (3) PC&PEP. 
Based on the results of the interim analysis, a total sample of 72 evaluable patients was 
required (α = 0.029 (one-sided), power of 80%; Table 1). 
Data analysis
Data were analyzed using the Statistical Package SPSS version 15 and STATA version 
10. Descriptive statistics and frequency distributions were generated for the patients’ 
demographic, disease, and pain-related characteristics. Independent Student t tests 
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and χ2 analyses were performed to determine if there were diff erences in the baseline 
characteristics between patients randomized to SC and PC&PEP. 
An overall analysis was performed for the pain intensities and daily interference using 
the above mentioned formula. Before that, for these outcome measures the missing 
values were substituted using an imputed method (i.e. multivariate regression). The 
diff erences between the groups for the other secondary end points were tested at T1, 
T2, and T3. 
For the primary and secondary end points, the distributions of scores were examined 
for normality by using the Shapiro-Wilk test. When the scores were not normally dis-
tributed, we used non-parametric tests (2-sample Mann-Whitney test), otherwise we 
used independent Student t tests. A P value of less than 0.05 (one-sided) was considered 
statistically signifi cant. The limited number of patients in the PC group did not allow for 
statistical testing. 
RESULTS
Patient Characteristics
In total, 73 patients with nociceptive cancer-related pain were included in the SC and 
the PC&PEP groups. One patient was not evaluable because he dropped out before T1 
(too ill; Figure 1). Patient characteristics of the evaluable patients are summarized in 
Table 2. The baseline results of the outcome measurements are reported in Table 3. No 
signifi cant diff erences were found in the demographic, disease, or baseline outcome 
measurements. 
Table 1. Assumptions for the original power analysis and the interim analysis (N=54) for average pain 
intensity.
Baseline
mean (sd)
2 weeks
mean (sd)
4 weeks
mean (sd)
8 weeks
mean (sd)
mPI
mean (sd)
1. Standard Care
Original power analysis
Interim analysis 
4.5 (2.0)
5.8 (1.4)
4.5 (2.0)
5.1 (1.7)
4.0 (2.0)
4.4 (1.9)
4.0 (2.0)
4.4 (1.8)
-0.31 (1.12)
-0.70 (1.51)
2. Pain Consult
Original power analysis
Interim analysis 
4.5 (2.0)
5.8 (1.5)
3.8 (2.0)
4.0 (1.7)
3.2 (2.0)
4.5 (2.8)
3.5 (2.0)
4.5 (2.8)
-0.93 (1.12)
-1.04 (1.27)
3. Pain Consult & PEP
Original power analysis
Interim analysis 
4.5 (2.0)
5.7 (1.3)
3.0 (2.0)
4.3 (1.5)
2.5 (2.0)
3.7 (1.4)
2.5 (2.0)
3.3 (2.2)
-1.61 (1.12)
-1.62 (1.33)
Assumptions of the original power analysis (italic), and the data of the interim analysis (N=54). mPI = 
weighted mean, an overall reduction over the 8-week period compared to baseline.
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Outpatient department and hospital admissions
Forty-eight patients were referred for a PC (Table 4). Thirteen patients (35%) received 
a PC as part of the standard care. Patients having a PC met the pain specialist for a 
median of 2 appointments (range 1 to 5). Diagnostic imaging (computed tomography/
magnetic resonance imaging) was requested in 57% of the patients, more frequently 
in the PC&PEP than the SC group (P=0.004). Twenty-six percent of the patients had a 
Eligibility assessed, 
consent obtained
RANDOMIZED
N=73
Standard Care
N=38
Pain Consult & PEP
N=35
WEEK 0
Completed assessments: 38
WEEK 0
Completed assessments: 35
WEEK 2 (T1)
Completed assessments: 37
WEEK 2 (T1)
Completed assessments: 34
Did not complete assessment: 1
    Too ill: 1
WEEK 4 (T2)
Completed assessments: 30
Did not complete assessment : 3
    Too ill: 2
    Refused: 1
WEEK 4 (T2)
Completed assessments: 31
Did not complete assessment: 3
    Too ill: 2
    Refused: 1
WEEK 8 (T3)
Completed assessments: 28
WEEK 8 (T3)
Completed assessments: 31
  Refused: 1
  Too ill: 2
  Died: 1
  Died: 1
  Too ill: 3
  Refused: 1
  Too ill: 1
  Too ill: 3
  Too ill: 1
Figure 1. Flow of patients through the trial
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hospital admission during the study, in 13% due to pain-related issues. The number of 
hospital admissions and the frequency radiotherapy used did not diff er between the 
groups (Table 4). 
Table 2. Baseline Demographic and Disease Characteristics
 
Total
(N=72)
Standard Care 
(N=37)
Pain Consult & PEP 
(N=35)
Gender male 25 (35%) 14 11
 female 47 (65%) 23 24
ECOG 0  7 (10%) 3 4
1 56 (78%) 29 27
2  9 (13%) 5 4
Age, mean (sd) 59 (11) 61 (12) 56 (10)
Tumor (n)
breast 24 (33%) 11 13
urogenital 12 (17%) 6 6
gastrointestinal 16 (22%) 10 6
lung  5 ( 7%) 2 3
melanoma  3 ( 4%) 1 2
head and neck  4 ( 6%) 3 1
ACUP  4 ( 6%) 2 2
sarcoma  2 ( 3%) 2 0
others  2 ( 3%) 0 2
Tumor status
Locally advanced 12 (17%) 5 7
Metastatic 59 (82%) 32 27
Unknown  1 ( 1%) 0 1
Anticancer treatment 
Chemotherapy 24 (33%) 12 12
Hormonal therapy 12 (17%) 7 5
No anticancer therapy 36 (50%) 18 18
Bisphosphonates  7 (10%) 3 4
Pain duration, months, median (IQR) 5 (3-14) 4 (2-8) 6 (3-24)
Number of pain locations
1 32 (44%) 17 15
2 31 (43%) 14 16
≥ 3 10 (14%) 6 4
Abbreviations: ACUP= Adenocarcinoma of Unknown Primary; IQR=Inter Quartile Range
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Table 3. Baseline Characteristics for Outcome Measures.
 
Standard Care 
(N=37)
Pain Consult & PEP 
(N=35)
BPI - Pain mean (sd)  
Average pain (0-10) 5.7 (1.3) 6.2 (1.5)
Worst pain (0-10) 7.9 (1.4) 8.1 (0.9)
Current pain (0-10) 4.2 (2.1) 5.0 (1.6)
BPI - Interference - mean (sd)  
Mean score (0-10) 4.4 (2.2) 4.6 (1.8)
Pain Management n( %)  
 Analgesic use  
No Analgesia 0 0
Acetominophen ± NSAIDs 37 (100) 34 (97)
Weak opioids  8 ( 22)  2 ( 6)
Strong opioids 19 ( 51) 23 (66)
Antidepressant drugs  2 ( 5)  1 ( 3)
Antiepileptic drugs  2 ( 5)  4 (11)
 Opioid prescription both ATC + PRN* 13 ( 50) 12 (48)
 MEDD mg/day, mean (sd) 84 ( 74) 70 (59)
 PMI  
Inadequate analgesia 14 ( 38) 14 (40)
Adequate analgesia 23 ( 62) 21 (60)
Pain Knowledge mean (sd) (0-100) 65 ( 12) 62 (13)
Abbreviations: MEDD = Morphine Equivalent Daily Dose; NSAID = Non-Steriodal Anti-Infl ammatory Drug; 
ATC = around the clock; PRN = as needed. *of the patients with an opioid prescription
Table 4. Pain Treatment during the study.
Total (N=72) 
N(%)
Standard Care (N=37) 
N(%)
Pain Consult & PEP (N=35) 
N(%)
P value
Patients with Pain Consult 48 (67) 13 (35) 35 (100) <0.001
Number appointments PC 0 24 (33) 24 (65) 0 <0.001
1 22 (31)  6 (16) 16 (46)
2-3 21 (29)  6 (16) 15 (43)
> 4  5 ( 7)  1 ( 3)  4 (11)
CT/ MRI 41 (57) 15 (41) 26 (74) 0.004
Hospital admissions 19 (26)  8 (22) 11 (31) 0.250
 due to pain  9 (13)  5 (14)  4 (11)
Radiotherapy 19 (26) 10 (27)  9 (26) 0.556
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Eff ect on Pain Intensity and Daily Interference over Time 
Figure 2 illustrates the mean reductions in pain intensity over time compared with 
baseline for patients randomized to SC and PC&PEP. For average pain intensity, the mΔPI 
was 1.13 for SC and 1.95 for PC&PEP (20% vs. 31%; P=0.03). For current pain intensity, 
the mΔPI was 0.67 for SC and 1.50 for PC&PEP (16% vs. 30%; P=0.016). No signifi cant 
diff erence was found between SC and PC&PEP groups for worst pain (1.16 vs. 1.28). For 
daily interference, the mean reduction was 0.11 for SC and 0.91 for PC&PEP (2.5% vs. 
20%; P=0.01; Figure 2). 
Changes in Medication
The number of patients with an opioid prescription, the type of prescription, the MEDD, 
and the adequacy of the prescription at the beginning of the study are listed in Table 
3. The percentage of patients with a WHO 3 opioid prescription increased from 51% at 
baseline to 64% at T3 in the SC group and from 66% to 77% in the PC&PEP group. At the 
separate time points, diff erences between SC and PC&PEP groups were not statistically 
signifi cant.
In the PC&PEP group, the percentage of patients with both an around-the-clock and 
an as needed (ATC+PRN) opioid prescription increased from 48% at baseline to 88% at 
T3. In the SC group, the percentage remained stable at 50%. The diff erence between the 
two groups was statistically signifi cant at T3 (P=0.003; Figure 3A). 
In the PC&PEP group, the median MEDD increased by 60 mg (range 60 to 2150 mg) 
over the eight weeks, compared with 33 mg (range 130 to 380 mg) in the SC group 
(Figure 3B). Diff erences between the two groups were not statistically signifi cant at any 
time point.
The adequacy of the analgesic prescription as measured with the PMI increased from 
62% to 75% (SC) and from 60% to 77% (PC&PEP) at T3 (not signifi cant). 
During the study, the percentage of patients with antidepressant or antiepileptic 
drugs did not diff er between the groups. 
Adherence to pain medication
Patients’ adherence in week 1&2 did not diff er between the groups (SC 79% and PC&PEP 
81%). In the last 2 weeks, mean adherence scores were changed to 74% and 85%, re-
spectively (P=0.028; Figure 3C). 
Patients’ Pain knowledge
Patients’ pain knowledge was measured at baseline and after 2 weeks. The baseline data 
are described in Table 3 and did not diff er. At week 2, the level of pain knowledge (0 to 
100) was signifi cantly better after randomization to PC&PEP (71, SD=13) than to SC (64, 
SD=10); P=0.002). 
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Figure 2. Mean changes in pain scores and daily interference, compared to baseline, over time in the 
Standard Care (N=37) and Pain Consult & PEP (N=35).
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Figure 3. Opioid analgesics. A. Percentage of patients with ATC + PRN opioids; B. Median change in total 
dose of opioid analgesics as prescribed (morphine equivalent daily dose), compared to baseline; C. Mean 
adherence week 1&2, week 3&4 and week 7&8. 
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Before the change in study design, 20 patients were randomized for a PC. The baseline 
characteristics of the group with PC were comparable with the SC and PC&PEP groups 
(Supplementary Tables S1-S3). For the PC group, the mΔPI was 1.58 for average pain; 
1.03 for current pain; 1.16 for worst pain. The reductions in pain were larger than the 
reductions found in the SC group but smaller than the reductions in the PC&PEP group. 
The reduction in mean daily interference was 1.06. Because the study was underpowered 
for a three-arm design, statistical testing was not performed (Supplementary Table 4). 
DISCUSSION
In the present study in oncology outpatients with pain, a PC combined with a PEP is 
more eff ective than SC in reducing average and current pain intensity and the interfer-
ence by pain in daily living. In addition, patients’ knowledge and adherence increased 
signifi cantly. To the authors’ knowledge, this is the fi rst study demonstrating a long-term 
eff ect of an intervention on daily interference. 
Various articles measured the eff ect of PEP or a pain protocol on daily interfer-
ence8-9,11,13-15,19-21,23-24,28, but only two studies found a signifi cant, although short-term 
eff ect15,24. A possible explanation why we found a signifi cant eff ect over the 8-week 
period in our study is that, in addition to PEP, the patients in the intervention group 
were monitored weekly by our specialized nurses. Thereby the pain treatment could be 
changed rapidly and PEP could be repeated, adjusted to patients’ daily life. 
In all PEP studies, pain intensity was an outcome measure. However, contrary to our 
study, 3 of 18 studies did not describe how they defi ned pain intensity10,21,26 and 5 of 18 
studies did not report all measured pain intensities7,11-12,15,19,21, preventing proper inter-
pretation of the results of these studies7. In this study, we found a comparable decrease 
in average pain intensity and current pain intensity as was found in the meta-analysis 
of Bennett et al.28. However, the results of this meta-analysis are diffi  cult to interpret 
because it is unclear if they included the overall results over the assessment periods. In 
addition, as they described in their discussion, they did not consider the duration of the 
assessment periods in the studies, which varied between 5 days20 and 6 months13. Unlike 
Bennett et al., we could not show an eff ect in worst pain intensity. It is possible that our 
patients, experiencing less average pain and less interference by pain in daily living, 
increased their daily activities until the occurrence of painful moments. The specialized 
nurses who educated the patients using PEP, indeed aimed to improve patients’ daily 
activity level. 
Unlike our study, most of the articles regarding PEP or a pain protocol did not substan-
tiate the sample size with a power analysis7,9-10,13,15,18,20-21,23-27,31 or studied small groups of 
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patients (< 50 patients) 20-21,24,26-27. Five studies reported the PMI34. Like the present study, 
all found no eff ect in PMI 10-11,14,19,24. Only Syrjala et al. 13 found a signifi cant eff ect in MEDD. 
Seven studies described the results of patient adherence to their analgesics. Four 
studies described no diff erences in adherence9,17,19,23, three other studies were able to 
found an increase in adherence13,21,25. However, 5 of these 7 studies used a question-
naire to measure adherence, like the Morisky questionnaire15,19,21,23,25, whereby they ask 
for patients’ perception and therefore did not actually measure medication adherence. 
The 2 other studies measured actual analgesic use in a medication diary9,17; both found 
no signifi cant eff ects on adherence to opioids. In this study, we measured adherence 
using MEMS. However, in an earlier study, we demonstrated that adherence measured 
with a medication diary and with MEMS gave comparable results35. Possibly, our weekly 
reinforcement of information may have increased the adherence to the analgesics. 
In the present study, 59% of the included patients had a prescription for strong opi-
oids, and 49% of the included patients already had a prescription for both ATC+PRN 
opioids at baseline, as advised by various national and international pain guidelines29-30. 
This contrasts with the study by Miaskowski et al.17, the only PEP study that described 
the analgesic prescription. In that study, 29% of the included patients had an ATC+PRN 
prescription for their opioids at baseline. Moreover, in our study patients’ pain knowl-
edge was higher at baseline than in previous studies that used the same questionnaire 
(64% vs 55%)12,31. In addition, 35% of the patients in de SC group were referred for a 
PC. At our outpatient clinic, therefore, doctors pay attention to cancer pain treatment. 
Nevertheless, we were able to further optimize pain treatment. At T3, 50% of patients 
randomized to SC and 88% of patients randomized to PC&PEP were given a prescription 
for ATC+PRN opioids. This again contrasts with the study by Miaskowski et al.17, in which 
37% of the patients in the intervention group had a prescription for ATC+PRN opioids at 
the end of their study17. 
The most important limitations of this study were the slow accrual and change in 
study design. In a previous study performed at the same outpatient clinic, we identifi ed 
107 patients with moderate or severe pain in one week33. Despite the apparent feasibil-
ity, it proved very diffi  cult to accrue patients for this study. The major reasons for the 
slow accrual were the strict exclusion criteria we used. Patients who had radiotherapy 
either planned or started within the two weeks before inclusion were excluded. Patients 
were also excluded when they already had been referred to a pain specialist or already 
had received pain education. Because the recruitment of our study was conducted 
through oncology health care professionals, we were dependent on the oncologists for 
inclusion, and therefore we were not able to screen all patients ourselves. During the 
study, we took a sample of 100 patients who used WHO analgesics and checked whether 
they were eligible. Patients were not eligible because of concurrent radiotherapy (28%), 
earlier referral to a pain specialist (15%), language barrier (8%), hospitalization (not for 
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pain) (10%), and other exclusion criteria (17%). Of the remaining 22 patients, we could 
not fi nd a note about patients’ pain in the medical record, so eligibility remained unclear. 
The slow accrual forced us to change our study design into a two group RCT, preventing 
us from assessing the contribution of a PC or PEP separately. However, it is reasonable 
that patient education and monitoring has an added value to a PC, because one-third of 
the SC also received a PC and the diff erences in pain treatment between SC and PC&PEP 
were limited. We could not prevent a referral to a pain specialist because in our hospital 
this referral often is considered as part of the standard pain treatment. However, this 
does not take place systematically. Our patients did not receive any form of palliative 
service in the outpatient clinic or in the community. During this study, the patients could 
be admitted to the unit for Palliatieve Care and Symptom Control. In the SC, 4 of the 37 
patients (11%) and in the PC&PEP 7 of the 35 patients (20%) were admitted to this unit 
during the study. However, during this study, PEP was not embedded in the standard 
care at this unit or at the outpatient clinic. In this study we investigated the added value 
of a systematic referral to a pain specialist (PC) and PEP in comparison with the SC. 
In conclusion, PC&PEP improves overall pain intensity, daily interference, patient 
adherence and pain knowledge in oncology outpatients. 
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Table S1. Baseline Demographics and Disease Characteristics.
Total
(N=91)
Standard Care 
(N=37)
Pain Consult & PEP
(N=35)
Pain Consult 
(N=19)
Gender  male 31 (34%) 14 11 6
female 60 (66%) 23 24 13
ECOG  0 9 (10%) 3 4 2
1 67 (73%) 29 27 11
2 15 (17%) 5 4 6
Age, mean (sd) 58 (11) 61 (12) 56 (10) 57 (12)
Tumor, n
Breast 29 (32%) 11 13 5
Urogenital 20 (22%) 6 6 8
Gastrointestinal 17 (19%) 10 6 1
Lung 6 (7%) 2 3 1
Melanoma 5 (5%) 1 2 2
Head and neck 4 (4%) 3 1 0
ACUP 5 (5%) 2 3 0
Sarcoma 2 (2%) 2 0 0
Others 3 (3%) 0 1 2
Tumor status
Locally advanced 19 (21%) 5 8 6
Metastatic 71 (78%) 32 26 13
Unknown 1 (1%) 0 1 0
Anticancer treatment
Chemotherapy 32 (35%) 12 12 8
Hormonal therapy 12 (13%) 7 5 0
No anticancer therapy 47 (52%) 18 18 11
Biphosphonates 10 (11%) 3 4 3
Pain duration (months), 
median (IQR) 5 (3-16) 4 (2-8) 6 (3-24) 10 (2-17)
Number of pain locations
1 41 (45%) 17 15 8
2 37 (41%) 14 16 7
≥3 14 (15%) 6 4 4
Abbreviations: ACUP= Adenocarcinoma of Unknown Primary; 
IQR=Inter Quartile Range.
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Table S2. Baseline Characteristics for Outcome Measures.
 
Standard Care 
(N=37)
Pain Consult & PEP 
(N=35)
Pain Consult 
(N=19)
BPI - Pain mean (sd)  
Average pain (0-10) 5.7 (1.3) 6.2 (1.5) 6.0 (1.8)
Worst pain (0-10) 7.9 (1.4) 8.1 (0.9) 7.8 (1.4)
Current pain (0-10) 4.2 (2.1) 5.0 (1.6) 5.0 (1.9)
BPI - Interference - mean (sd)  
Mean score (0-10) 4.4 (2.2) 4.6 (1.8) 5.5 (1.5)
Pain Knowledge mean (sd) (0-100) 65 (12) 62 13) 65 (13)
Pain Management n( %)  
 Analgesic use  
No Analgesia 0 0 0
Acetominophen ± NSAIDs 37 (100) 34 (97) 16 (84)
Weak opioids  8 ( 22)  2 ( 6)  2 (11)
Strong opioids 19 ( 51) 23 (66) 12 (63)
Antidepressant drugs  2 ( 5)  1 ( 3) 0
Antiepileptic drugs  2 ( 5)  4 (11)  1 ( 5)
 PMI  
Inadequate analgesia 14 (38) 14 (40)  9 (47)
Adequate analgesia 23 (62) 21 (60) 10 (53)
 Opioid prescription both ATC + PRN* 13 (50) 12 (48)  7 (50)
 MEDD mg/day, mean (sd) 84 (74) 70 (59) 93 (90)
Abbreviations: MEDD = Morphine Equivalent Daily Dose; NSAID = Non-Steriodal Anti-Infl ammatory Drug; 
ATC = around the clock; PRN = as needed. *of the patients with opioid prescription
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Table S3. Pain Treatment during the study.
Total 
(N=91) 
N(%)
Standard Care 
(N=37) 
N(%)
Pain Consult & PEP 
(N=35) 
N(%)
Pain Consult 
(N=19) 
N(%)
Patients with Pain Consult 67 (74) 13 (35) 35 (100) 19 (100)
Number appointments PC 
0 24 (26) 24 (65) 0 0
1 30 (33) 6 (16) 16 (46) 8 (42)
2-3 31 (34) 6 (16) 15 (43) 10 (53)
> 4 6 ( 7) 1 ( 3) 4 (11) 1 ( 5)
CT/ MRI 55 (60) 15 (41) 26 (74) 14 (74)
Hospital admissions 25 (27) 8 (22) 11 (31) 6 (32)
due to pain 12 (13) 5 (14) 4 (11) 3 (16)
Radiotherapy 21 (23) 10 (27) 9 (26) 2 (11)
Table S4. Overall reduction in pain and interference.
Standard Care
(N=37)
Pain Consult
(N=19)
Pain Consult & PEP 
(N=35)
mΔPI Average pain 1.13 1.58 1.95
mΔPI Current pain 0.67 1.03 1.50
mΔPI Worst pain 1.16 1.16 1.28
mΔPI Daily interference 0.11 1.06 0.91
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ABSTRACT 
The eff ectiveness of an opioid rotation to parenteral hydromorphone in advanced cancer 
patients has never been investigated. Therefore, the purpose of this study was to inves-
tigate the analgesic effi  cacy and side eff ects of parenteral hydromorphone on serious 
cancer-related pain. We included 104 consecutive advanced cancer patients who were 
extensively pretreated with opioids. They were rotated to parenteral hydromorphone 
because they failed to achieve adequate pain relief on other opioids. Pain intensity and 
side eff ects were daily assessed. The moment of adequate pain control was defi ned as 
the fi rst of at least 2 consecutive days when the mean pain intensity at rest was ≤ 4 (on 
a 0-10 numeric rating scale) and side eff ects were tolerable. 
The reasons for rotation to parenteral hydromorphone were inadequate pain control 
with/without expected delivery problems due to high opioid dosages (n=61) and in-
tolerable side eff ects with persistent pain (n=43). Adequate pain control was achieved 
in 86 patients (83%) within a mean of 5 days. Eight of 86 patients still had side eff ects, 
but these were scored as acceptable. The mean pain intensity at rest decreased from 5.4 
[standard deviation (sd)=2.1] to 2.4 (sd=1.5; p<0.001). The median failure-free treatment 
period was 57 days and covered a substantial part of the median survival of 78 days in the 
responding patients. In conclusion, in advanced cancer patients with serious unstable 
cancer-related pain refractory to other opioids, continuous parenteral administration 
of hydromorphone often results in long-lasting adequate pain control and should be 
considered even after extensive pretreatment with opioids. 
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INTRODUCTION 
Pain is a serious problem in patients with advanced solid cancer. Two thirds of these 
patients experience pain of whom 20% grade their pain as moderate to severe1. The 
World Health Organization set up guidelines for treating chronic cancer pain up to 
high doses of around-the-clock opioids, striving for an acceptable pain control for the 
majority of cancer patients2-3. However, despite following these guidelines accurately, 
10-30% of patients do not achieve adequate pain relief, mainly because of uncontrolled 
side eff ects restraining them from further dose increment3. For these patients, an opioid 
rotation, a change in opioid or route of administration has been shown to be benefi cial 
in several studies4-5. Parenteral administration of opioids (here defi ned as subcutaneous 
or intravenous) is especially useful for rapid titration in case of severe pain, but it is also 
indicated for patients with pain in whom dose escalations are needed to doses that are 
no longer convenient for oral use6-7. When high doses of opioids are indicated, potent 
opioids that can still be delivered in small volumes are necessary, especially when sub-
cutaneous administration is desirable8. When parenteral treatment fails, more invasive 
techniques like epidural and intrathecal opioid treatment are possible, although these 
techniques are more expensive and hazardous8. 
Hydromorphone is a semisynthetic derivate of morphine, with comparable effi  cacy 
and side eff ects to morphine when administrated subcutaneously in low concentra-
tions9. Since hydromorphone is more lipophilic than other opioids9-10 it can be admin-
istrated subcutaneously in highly concentrated solutions, making it particularly useful 
for subcutaneous administration when high doses of opioids are needed7,9,11. Based on 
this knowledge, it can be hypothesized that in case of inadequate pain control and/or 
uncontrolled side eff ects in patients who already use opioids in high doses for moder-
ate to severe pain, rotating from a certain opioid to parenteral hydromorphone might 
be a useful alternative. In practice, this situation will especially occur in cancer patients 
with progressive disease for whom antitumor therapy is no longer available and life 
expectancy, therefore, is limited. These patients are also often treated with earlier opioid 
rotations in an eff ort to treat pain with tolerable side eff ects. However, data on the eff ect 
of parenteral hydromorphone in such patients are lacking. 
We therefore performed a descriptive, retrospective study in extensively pretreated 
advanced cancer patients with inadequate pain control or uncontrolled side eff ects on 
the current opioids who were rotated to parenteral hydromorphone. The objective of 
this study was to investigate the analgesic effi  cacy and side eff ects of opioid rotation to 
parenteral hydromorphone, continuously administrated, on serious cancer-related pain 
among this patient population. 
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METHODS
Data were c ollected in our 13-bed Unit for Palliative Care and Symptom Control (PCSC 
unit) in the Erasmus MC Daniel den Hoed Cancer Center in the Netherlands. Most of 
the patients admitted to our PCSC unit have already been set on pain medication by 
their general practitioner or treating physicians, either from the cancer center or from 
other hospitals. Patients with severe pain despite the use of around-the-clock opioids or 
patients who suff er intolerable side eff ects to the used opioids are admitted for titration 
of parenteral opioids. At our PCSC unit, we generally use morphine or fentanyl for par-
enteral administration, depending on the opioid used before. In general, opioid rotation 
to another opioid is used in case of inadequate pain control combined with limiting 
opioid-related side eff ects; otherwise, dose escalation is applied with the opioid in use. 
Patients who suff er intolerable side eff ects on morphine and fentanyl and patients with 
persistent pain despite multiple dose escalations, particularly when high doses of sub-
cutaneous opioids are needed to such an extent that delivery problems (are expected 
to) occur because of needed volumes, can be rotated to parenteral hydromorphone. 
The decision for rotating to parenteral hydromorphone is made by our multidisciplinary 
pain team. In general, patients who are rotated to parenteral hydromorphone start with 
50-75% of the equianalgesic dose of the former opioid to allow for incomplete cross 
tolerance12. Published equianalgesic dose tables were used10,13-14. The subcutaneous 
route is preferred unless the infusion volume of the opioid administrated per hour is too 
large. Parenteral hydromorphone is not commercially available in the Netherlands, but 
can be prepared by our hospital pharmacy in a concentration of 10 mg/ml. 
In this retrospective study, consecutive patients with nociceptive pain set on paren-
teral hydromorphone between December 2004 and June 2010 were included, thereby 
using the unit’s standard systematic registration of pain intensity and side eff ects. 
Baseline characteristics including age, gender, type of cancer, tumor status, anti-tumor 
therapy (radiotherapy, chemotherapy, and hormonal therapy), prior analgesic prescrip-
tion, pain intensity, side eff ects, and the reason for rotation to hydromorphone were 
obtained from medical records. Reasons for rotation to hydromorphone were classifi ed 
as inadequate pain control {pain intensity > 4 [on a 0-10 numerical rating scale (NRS)] or 
uncomfortable} often while reaching the maximum feasible volume for subcutaneous 
administration of morphine or fentanyl, and intolerable (moderate to severe; see next 
paragraph) opioid-induced side eff ects (i.e., nausea or vomiting, constipation, confusion, 
somnolence, hallucinations, and myoclonus). In case of a combination of intolerable 
side eff ects and persistent pain or delivery problems of subcutaneous administration of 
large volumes, the reason for rotation was classifi ed as intolerable side eff ects. 
After starting parenteral administration of hydromorphone, pain intensity and side 
eff ects were recorded twice daily. Patients were asked to rate their pain intensity at rest 
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and with movement on the NRS15. The mean pain scores were calculated as the means 
of two pain intensity scores per day for pain at rest and pain with movement separately. 
Side eff ects were systematically rated using a Likert scale as none, mild, moderate, or se-
vere. Side eff ects were further dichotomized into tolerable (none or mild) or intolerable 
(moderate or severe) categories. The used dosages of the diff erent opioids were con-
verted to oral morphine equivalent daily doses (MED, in milligrams per day) according to 
published equianalgesic dose tables: oral morphine 60 mg/day = parenteral morphine 
20 mg/day = transdermal fentanyl 25 mcg/hr = parenteral fentanyl 25 mcg/hr = oral 
oxycodone 30 mg/day = oral hydromorphone 8 mg/day = parenteral hydromorphone 
4 mg/day13-14,16-17.
The eff ectiveness of continuous administration of parenteral hydromorphone was 
evaluated by determining the percentage of patients whose pain got adequately 
controlled with continuous administration of parenteral hydromorphone without 
intolerable side eff ects, the change in mean pain intensity at rest and mean pain with 
movement in these patients, and the time needed to achieve adequate pain control. 
The moment that adequate pain control was reached was defi ned as the fi rst day of 
at least 2 consecutive days in which the mean pain score at rest was 4 or less18-19, or in 
case pain measurement was not reported, patients and physicians were documented to 
be satisfi ed both in the absence of intolerable side eff ects. Moreover, to get an impres-
sion of the duration of the eff ect of parenteral hydromorphone, the failure-free period 
was determined among all patients who reached adequate pain control after rotation 
to parenteral hydromorphone. Failure-free period was defi ned as the period from the 
start of hydromorphone until death or the application of more invasive techniques. 
In some patients pain was adequately controlled with dosages of hydromorphone for 
which rotation back to an oral or transdermal opioid formulation was feasible. These 
patients were not considered as failures on parenteral hydromorphone and therefore 
were included in the calculation of the failure-free treatment period. Overall survival 
was calculated from the start of hydromorphone until death or end of the study. 
Statistical analysis
Data were analyzed using the Statistical Package for the Social Science for Windows 
version 15.0. Descriptive statistics was used to describe patients’ sociodemographic and 
medical characteristics. Diff erences in mean pain intensity overtime were tested with 
the t test. The failure-free treatment period and overall survival was visualized using 
the Kaplan-Meier method. July 31, 2010 was the censoring date for survival. Reported p 
values are two-tailed, and p< 0.05 was considered to be statistically signifi cant. 
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RESULTS
One hundred and four consecutive patients were rotated to hydromorphone between 
December 2004 and June 2010. The baseline characteristics are shown in Table 1. All pa-
tients had advanced cancer, predominantly lung (18%), urological (17%), breast (14%), 
gastrointestinal (14%), or gynecological carcinoma (9%). The main reasons for rotation 
to parenteral hydromorphone were inadequate pain control combined with/without 
Table 1. Patient characteristics.
N (%)
Age (years), mean (sd) 57 (13.5)
Gender
 Male 57 (55%)
 Female 47 (45%)
Stage of disease
 Metastatic disease 91 (88%)
 Local recurrence 13 (13%)
More than one pain location 82 (79%)
Anticancer treatment at start hydromorphone
 No anticancer therapy 84 (81%)
 Radiotherapy (within 2 weeks before start) 12 (12%)
 Chemotherapy 5 (5%)
 Hormonal therapy 3 (3%)
Use of atc opioids until start hydromorphonea
 Oral morphine  5 (5%)
 Parenteral morphine 14 (13%)
 Transdermal fentanyl 38 (37%)
 Parenteral fentanyl 41 (39%)
 Oral oxycodone  6 (6%)
 Oral hydromorphone  5 (5%)
Oral morphine equianalgesic dose (mg), median (range) 600 (72-2,592)
Atc opioids ever used before hydromorphone
 Fentanyl (transdermal or parenteral) 92 (88%)
 Morphine (oral or parenteral) 66 (63%)
 Oxycodone (oral) 30 (29%)
 Tramadol (oral) 21 (20%)
 Hydromorphone (oral)  7 (7%)
 Methadone (oral)  1 (1%)
HM hydromorphone, SD = standard deviation, atc = around the clock 
a Five patients used combination of analgesics
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expected delivery problems due to high opioid dosages [n=61, (59%)] and intolerable 
side eff ects with persistent pain [n=43, (41%); Figure 1]. 
All patients had received opioids before the start of parenteral hydromorphone (Table 
1); 19 patients (18%) used morphine, and 79 patients (76%) used fentanyl as last opioid 
before the start of hydromorphone. Patients included in this study had serious cancer-
related pain, which became obvious in the fact that most patients were extensively 
pretreated; 91 patients (88%) had been treated with two or more opioid rotations (drug 
and/or route) before rotating to hydromorphone. In addition, before rotating to paren-
teral hydromorphone, 74% of the patients had ever used at least two diff erent types of 
opioids and 31% at least three diff erent opioid types (Table 1). 
104 patients
Pain and/or delivery 
problems (n=61) Side effects (n=43)
Reached adequate 
pain control* 
(n=52)
Did not reach 
adequate pain control* 
(n=9)
Did not reach 
adequate pain control*
(n=9)
Reached adequate 
pain control*
(n=34)
Died with adequate 
pain treatment 
(n=33)
Rotated to oral/
transdermal opioids 
(n=7)
Still using HM (n=5)
Ultimately rotated to spinal 
analgesia (n=6) or treated by 
nerve block (n=1)
Died with adequate 
pain treatment 
(n=16)
Rotated to oral/ 
transdermal opioids 
(n=10)
Still using HM (n=3)
Ultimately rotated to 
spinal analgesia (n=5)
Figure 1. Opioid rotation to parenteral hydromorphone: summary of indications and clinical eff ectiveness
* adequate pain control = mean pain score in rest ≤ 4 (or when patients and physicians were satisfi ed) in 
the absence of intolerable side eff ects
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The median oral MED was 600 mg/day (range 72-2,5 92 mg/day) before the start of 
hydromorphone (Table 1). Ninety-one patients were rotated to subcutaneous adminis-
tration and 13 patients to intravenous administration of hydromorphone. The median 
daily dose of parenteral hydromorphone at start was 48 mg/day (range 5-216 mg/day). 
Achievement of pain control
Adequate pain control (without intolerable side eff ects) was achieved in 86 out of 104 
patients (83%) within a mean of 5.0 days [standard deviation (sd) = 3.4; Figure 1]. There 
was no relationship between number of opioids patients used before rotating to hydro-
morphone and percentage of patients achieving adequate pain control on parenteral 
hydromorphone. Before this rotation, 54 patients (52%) had side eff ects [mostly somno-
lence (n=22) or nausea (n=18)]. Eight of the 86 patients had side eff ects at adequate pain 
control [mostly nausea (n=3), constipation (n=4)], although these patients and their 
physicians were satisfi ed with the management of the side eff ects and both were unwill-
ing to change policy. The mean pain intensity at rest in these 86 patients signifi cantly 
decreased from 5.4 (sd =2.1) to 2.4 (sd=1.5; n=78; p< 0.001). The mean pain intensity 
with movement signifi cantly decreased from 7.4 (sd=1.6) to 3.8 (sd=1.5; n=53; p< 0.001). 
Among the 61 patients who were rotated to hydromorphone mainly because of 
inadequate pain control with/without (expected) volume problems with parenteral ad-
ministration, 52 (85%) reached adequate pain control. In addition, a subgroup analysis, 
comparing patients with and without expected delivery problems due to high opioid 
dosages, showed similar percentage of patients receiving adequate pain control (90% 
vs. 83%; p=0.47). Among the 43 patients who were rotated to hydromorphone mainly 
because of opioid-related side eff ects, adequate pain control with tolerable side eff ects 
was reached in 34 (79%, Figure 1). In both groups of successfully treated patients, mean 
pain intensity scores at rest and with movement decreased signifi cantly with titration of 
hydromorphone (Table 2). 
Eighteen patients (17%) did not reach adequate pain control. Six patients died before 
reaching adequate pain control with parenteral hydromorphone (2-13 days); two of 
them were treated with palliative sedation in their terminal phase because of refractory 
pain and dyspnea. Twelve patients failed because of inadequate pain control and/or 
uncontrolled side eff ects. Ten of them were given spinal analgesia; one patient received 
a nerve block, and in one patient the intervention used was unknown.
Duration of eff ect on hydromorphone and overall survival
Among the 86 patients who achieved adequate pain control on parenteral hydromor-
phone, 74 patients (86%) did not undergo further invasive procedures, 49 patients (57%) 
died while still on parenteral hydromorphone, 17 patients (20%) were rotated to oral or 
transdermal opioids, and eight patients (9%) were still using parenteral hydromorphone 
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at the time of data collection. Eleven patients ultimately rotated to spinal analgesia and 
one patient received a nerve block (Figure 1). 
The m edian failure-free treatment period of the 86 responding patients was 57 days 
(range: 2-1,094 days), whereas their median duration of survival was 78 days (range 
3-1,094 days). At the end of follow-up, ten patients were still alive (Figure 2). 
Table 2. Pain intensity scores in patients successfully rotated to parenteral hydromorphone.
Total (n=86) Pain (n=52) Side eff ects (n=34)
T0 T1 T0 T1 T0 T1
Daily dose hydromorphone (mg), 
median (range)
48 (5-144) 48 (5-144) 48 (12-144) 65 (10-144) 24 (5-72) 34 (5-96)
Pain at rest, mean (sd) 5.4 (2.1) 2.4 (1.5)* 5.7 (2.2) 2.6 (1.5)* 4.8 (1.8) 2.1 (1.4)*
Pain with movement, mean (sd) 7.4 (1.6) 3.8 (1.5)* 7.5 (1.7) 3.5 (1.6)* 7.1 (1.6) 4.2 (1.4)*
* p < 0.001; T0 baseline, T1 at adequate pain control
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Figure 2. Failure-free treatment duration and overall survival in patients who reached adequate pain 
control on parenteral hydromorphone (n=86) 
Overall survival was calculated from the start of hydromorphone until death or end of the study (black 
dotted line); duration of hydromorphone use (grey dashed line). Failure-free survival was defi ned as the 
period from the start of hydromorphone until death or the application of more invasive techniques (light 
grey line). 
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Other possible infl uencing factors
At baseline, 100 patients (96%) used adjuvant analgesics while rotated to parenteral 
hydromorphone (Table 3). Ninety-one of them used two or more adjuvant analgesics 
at baseline. In the 86 patients who reached adequate pain control, adjuvant analgesics 
were changed in 41 of them (Table 3). For example, six patients already used S(+)-
ketamine before starting parenteral hydromorphone, three of them stopped with 
S(+)-ketamine before their pain was adequately treated. Thirteen other patients started 
with S(+)-ketamine between the start of parenteral hydromorphone and the moment 
adequate pain control was achieved (Table 3). A subgroup analysis comparing patients 
with and without the use of S(+)-ketamine, showed similar percentages of patients 
achieving adequate pain control (87% vs. 82%, p=0.54). Although a longer period was 
needed to achieve adequate pain control in those patients who used S(+)-ketamine 
compared to those who did not (median of 7 vs. 3 days; p=0.004), the median dosage 
of hydromorphone at start and at the moment of reaching adequate pain control was 
similar in both groups. Haloperidol was added in four patients to control their side ef-
fects. Dexamethasone was added in three patients while having radiotherapy (Table 3). 
Thirteen patients received radiotherapy within two weeks before starting parenteral hy-
dromorphone or during therapy with hydromorphone (Table 1), and achieved adequate 
pain control within a median of 6 days. 
Table 3. Adjuvant (analgesic) medication
All patients
(n=104) All patients who reached adequate pain control (n=86)
At the start of 
hydromorphone treatment, n (%)
At the start of 
hydromorphone treatment, n (%)
At adequate 
pain control, n (%)
Acetaminophen 89 (86) 74 (86) 74 (86)
NSAIDs 77 (74) 65 (76) 68 (79)
S(+)-ketamine 9 ( 9) 6 ( 7) 16 (19)
Antidepressants 19 (18) 16 (19) 11 (13)
Anticonvulsants 48 (46) 39 (45) 15 (18)
Dexamethasone 5 ( 5) 5 ( 6) 8 ( 9)
Haloperidol 15 (14) 10 (12) 14 (16)
Methylphenidate 3 ( 3) 3 ( 4) 4 ( 5)
NSAIDs nonsteroidal anti-infl ammatory drugs
DISCUSSION
In the present study, we have shown that parenteral hydromorphone is highly eff ec-
tive in advanced cancer patients with serious cancer-related pain who were extensively 
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pretreated with opioids. Eighty-three percent of the patients achieved adequate pain 
control with tolerable side eff ects within a mean of 5 days. Moreover, among 86% of 
these patients, the pain was adequately controlled until death without the need of fur-
ther invasive procedures. The median failure-free treatment period of 57 days covered 
a substantial part of the median survival of 78 days in the responding patients. Thus, 
in advanced cancer patients with severe cancer-related pain despite the use of several 
lines of opioids, rotation to continuous parenteral administration of hydromorphone 
seems an elegant, highly eff ective option. 
For patients who fail on a certain opioid, opioid rotation is regularly used, either as 
a change in the opioid drug or as a change in the route of administration. However, 
it is unknown whether opioid rotation is the choice to make in extensively pretreated 
cancer patients. In Table 4 all currently published prospective and retrospective studies 
on opioid rotation are described. In most studies the patient population was unclearly 
described. Moreover, only fi ve studies gave some indication that advanced cancer pa-
tients were included in the study20-24. Unfortunately, these studies reported only over a 
short period of follow-up (7-28 days) and clear information on previous opioid use was 
lacking (Table 4). Finally, none of these studies reported a rotation to parenteral hydro-
morphone. Thus, with the current study, we are the fi rst to show that an opioid switch to 
parenteral hydromorphone in a well-described, extensively pretreated advanced cancer 
patient population is a suitable and highly eff ective possibility.
In advanced cancer patients, subcutaneous administration of opioids is preferable to 
intravenous administration since it is more useful in the outpatient setting, has a lower 
risk of complications like infections, and is less expensive11,25. Since hydromorphone can 
be administered in high concentrations in very low volumes subcutaneously, it has been 
found to be useful when high doses of opioids are needed11. In our center, the maximum 
volume given subcutaneously is 2 ml/h for morphine and hydromorphone and 4 ml/h 
for fentanyl. Morphine and hydromorphone are available in concentrations of 10 mg/ml; 
fentanyl in a concentration of 50 μg/ml. In a substantial part of our patients, it was not 
possible to titrate morphine or fentanyl subcutaneously anymore because of too large 
volumes needed. To circumvent this problem, higher concentrations of opioids per mil-
liliter could be prepared. However, in our experience, this often leads to an unacceptable 
high percentage of annoying local skin infi ltrations. 
There are several limitations that should be considered in interpreting the results 
of our study. First, it is a retrospective study. However, even though the defi nitions 
of the outcome measures were made retrospectively, the patients were evaluated 
prospectively for pain intensity and side eff ects. Due to the retrospective design, we 
were not able to give a complete overview of the analgesics patients had used before 
they were treated in our hospital. It is thus likely that the analgesics presented in Table 
1 are an underestimation of the previously used analgesics. Second, this study was a 
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single-center study, which hampered the extrapolation of the results. Third, adequate 
pain control could be due to concomitant treatment with S(+)-ketamine or undergoing 
radiotherapy instead of an eff ect of hydromorphone alone. A pain-reducing eff ect of us-
ing S(+)-ketamine could not be excluded, although it seems not very likely. Besides the 
pain-reducing eff ect, S(+)-ketamine has been suggested to restore opioid sensitivity for 
its analgesic eff ects thereby diminishing the opioid doses needed to achieve adequate 
pain control. Due to the fact that the success rate in patients with and without S(+)-
ketamine was the same in the subgroup analysis, the main eff ect we found in this study 
is most likely caused by hydromorphone. As far as radiotherapy is concerned, the eff ect 
of radiotherapy on pain relief can be expected after 2-4 weeks26-27. Given the fact that 
patients with radiotherapy received adequate pain control within a median of 6 days, a 
pain-reducing eff ect of radiotherapy in these patients cannot be fully excluded. 
In conclusion, in patients with advanced cancer and serious unstable cancer-related 
pain refractory to other opioids, parenteral continuous administration of hydromor-
phone seems eff ective and should be considered even after extensive pretreatment 
with opioids. In this vulnerable patient population, often in their last weeks to months of 
life, adequate pain management is of the utmost importance. However, until now, opi-
oid rotation is used by trial and error. For individual patients, underlying factors related 
to benefi cial and detrimental eff ects of specifi c opioids are unknown. For optimizing 
patient-tailored opioid therapy, insights in underlying pharmacodynamic mechanisms 
are eagerly awaited.
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Since 1990, the prevalence of cancer in the Netherlands has been increased with 3 – 
3.5% per year, mainly provoked by an increase in the national population, especially in 
the elderly. In 2010, 540 371 persons were living with cancer (twenty-years prevalence) 
in the Netherlands1-2. In cancer patients, pain is one of the most frequent and feared 
symptoms. The prevalence of cancer-related pain remained stable during the years; 
approximately 53% of the cancer patients experienced pain during their disease3. The 
aim of pain management is to reduce patients’ pain intensity to a tolerable level with 
acceptable side-eff ects. 
Cancer-related pain management consists of a combination of anti-tumor therapy 
and symptomatic pharmacotherapy. Although the World Health Organization (WHO) 
introduced the analgesic ladder in 1986, till today adequate analgesia can be achieved 
in approximately 76% (range 45% - 100%) of the patients with cancer-related pain4-5. 
Possible reasons for inadequate pain management are the complexity of pain problems 
in a substantial part of the cancer patients, and the existence of various barriers and 
misconceptions regarding pain and pain management in both health care professionals 
and patients. Therefore, attention to the improvement of pain management remains 
necessary (chapter 1).
Because the prevalence of cancer-related pain varied across the studies, we identifi ed 
the prevalence of cancer-related pain and the prevalence of inadequate pain relief at the 
outpatient clinic of the Erasmus MC Daniel den Hoed Cancer Center. Chapter 2 reports 
a cross-sectional survey among 915 adult cancer outpatients. Patients were asked to 
rate their pain on an 11-point numeric rating scale (NRS) of 0-106. A total of 246 of 915 
patients (27%) had pain or used analgesics in the past week. Of these patients, 180 
patients (73%) had been prescribed analgesics. Only 70% of patients with a prescription 
for analgesics had a prescription for ‘around the clock’ (ATC) analgesics, and 58% had 
access to ‘as needed’ (PRN) analgesics. Pain management was indicated as inadequate in 
158 of 244 patients (65%)7. A total of 125 patients had a prescription for ATC analgesics 
and were evaluable for adherence measurement. Adherence rates were calculated for 
ATC regimens (i.e. dose taken divided by dose prescribed, multiplied by 100) and were 
considered inadequate when below 100% of the dose prescribed. Overall, 91 patients 
(73%) adhered to their analgesic prescription. From this survey, we were not able to 
make clear why patients did not take their analgesics and why professionals did not give 
the most adequate analgesic prescription. Therefore, chapter 3 describes a systematic 
review of the literature to identify the major barriers hindering adequate pain manage-
ment and to give a critical appraisal of interventions aiming to overcome these barriers. 
Patients often impede their own treatment due to misconceptions about analgesics 
and their side-eff ects (e.g. concerned about addiction), non-adherence to their pre-
scribed analgesics, and poor communication of their pain and their concerns about pain 
to health care providers (e.g. concerned that increased pain means progression of dis-
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ease)8-18. The most frequently mentioned barriers in professionals (both physicians and 
nurses) that may hamper adequate pain management were: inadequate assessment of 
pain and pain management, patients’ reluctance to report their pain or to give a pain 
score, and inadequate knowledge of pain management (e.g. believe that morphine has 
an upper limit)19-25. This review identifi ed four interventions aimed to overcome these 
barriers: patient education, professional education, pain assessment and pain consulta-
tion. These interventions were always studied separately and were never combined in 
multidisciplinary study protocols. Studies on professional education and pain assess-
ment did not evaluate patients’ outcomes (e.g. pain intensity)26-29. In fi ve of the eleven 
RCTs on patient education (PEP) and the two RCTs on pain consultation, patients’ pain 
intensity decreased statistically signifi cantly, although the adequacy of pain treatment, 
adherence or interference with daily life did not change8,30-41. The sample size of these 
studies varied widely and patients’ follow-up diff ered per study (i.e. 5 days till 8 weeks). 
In addition, the RCTs measured diff erent types of pain intensity, and the results of the 
studies on patient education could even be fl attered because some of the studies did 
not report all measured pain intensities. 
One of the infl uencing factors of adequate pain management is patients’ adherence 
to analgesics. In cancer pain, adherence has been measured by self-report. Self-report, 
however, is limited by patients’ memory. Moreover, the use of medication diaries over 
time is variable and patients tend to complete them retrospectively42-45. Another indirect 
method is the Medication Event Monitoring System (MEMS), an electronic monitoring 
device. A MEMS vial is a standard medication vial with a cap containing a microproces-
sor that accurately records time and date of each opening and closing. Similar to all 
indirect adherence methods, MEMS does not confi rm ingestion of medication43. MEMS 
was never used in analgesic adherence measurement. In chapter 4, we determined the 
feasibility of MEMS vials in comparison with medication diaries in cancer patients with 
chronic pain on single as well as on multiple analgesic regimens. 
Forty-six patients with nociceptive pain caused by cancer were asked to use MEMS 
vials for their analgesics and to record their medication usage in a diary for four weeks. 
Seventy-nine percent of these patients used MEMS for the full four-week period; 70% 
did so for the diary. The majority of patients were satisfi ed with both MEMS and diary. 
Adherence data assessed by MEMS and diary were comparable. Subgroup analyses in 
patients using single and multiple analgesic regimens confi rmed the comparable use-
fulness of both methods. MEMS and a medication diary are equally useful for adherence 
measurement in analgesics. 
To improve patients’ pain treatment, we performed a multidisciplinary and multilevel 
randomized controlled trial. As identifi ed in chapter 3, interventions to diminish pro-
fessional-related and patient-related barriers were only studied separately, not in com-
bination. From the literature, these interventions did not unequivocally demonstrated 
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clinically relevant improvements in patients’ pain intensity. In chapter 5, we report the 
results of a randomized controlled trial (RCT) that tested the eff ectiveness of a pain con-
sult combined with PEP. The primary endpoint of this study was the overall reduction of 
average pain intensity over the 8-week study period with respect to baseline. 
Patients were initially randomly assigned to (1) standard care (SC), (2) pain consult 
(PC), or (3) pain consult combined with a patient Pain Education Program (PC&PEP). 
During the PC, a pain specialist determined if the cause of pain was clear; advised on 
anti-tumor therapy and optimized symptomatic treatment, as indicated. PEP consisted 
of patient-tailored pain education to enhance patients’ knowledge about pain and pain 
management and to stimulate patients’ help-seeking behavior, and weekly monitoring 
of pain and side-eff ects41. In January 2009, the three-arm study turned out to be not 
feasible because of slow accrual. Since then patients were randomized between (1) SC 
and (3) PC&PEP. In total, 37 patients were randomized to SC and 35 patients to PC&PEP. 
The overall reduction in pain intensity and daily interference was signifi cantly greater 
after randomization to PC&PEP than to SC (average pain 31% vs. 20%, P=0.03; current 
pain 30% vs. 16%, P= 0.016; daily interference 20% vs. 2.5%, P=0.01). Adequacy of 
pain management did not diff er between the groups. However, in the PC&PEP group 
the percentage of patients with both an ATC and a PRN opioid prescription increased 
from 48% at baseline to 88% after 8 weeks. In the SC group the percentage remained 
stable at 50%. The diff erence between the two groups was statistically signifi cant after 
8 weeks (P=0.003). Patients were more adherent to analgesics as measured with MEMS, 
after randomization to PC&PEP than to SC (P=0.03) and after 2 weeks the level of pain 
knowledge was signifi cantly better after randomization to PC&PEP than to SC (P=0.002). 
In conclusion, PC&PEP improves patients’ pain intensity, daily interference, patient 
adherence and patient knowledge in oncology outpatients. This study was the fi rst to 
show an eff ect of PEP in daily interference.  
As described in chapter 1, another reason why pain treatment is not always eff ective 
in all patients, is the complexity of pain in some patients. In our hospital, patients who 
suff er intolerable side eff ects on morphine and fentanyl, and patients with persistent 
pain despite multiple dose escalations, can be rotated to parenteral hydromorphone. 
Hydromorphone is a semi-synthetic derivate of morphine, with comparable effi  cacy 
and side eff ects to morphine. Hydromorphone can be administrated subcutaneously 
in highly concentrated solutions, making it particularly useful for subcutaneous ad-
ministration when high doses of opioids are needed46-47. Chapter 6 describes a study 
in which the analgesic effi  cacy and side eff ects of hydromorphone were investigated 
in advanced cancer patients with serious cancer-related pain. The reasons for rotation 
to parenteral hydromorphone were inadequate pain control with or without expected 
delivery problems due to high opioid dosages (n=61) and intolerable side eff ects with 
persistent pain (n=43). Before this rotation, 88% of the patients had been treated with 
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two or more opioid rotations. Adequate pain control was achieved in 86 patients (83%) 
within a median of 5 days. Eight of these 86 patients still had side eff ects, but these 
were scored as acceptable. The mean pain intensity at rest decreased from 5.4 (sd=2.1) 
to 2.4 (sd=1.5, P<0.001). The median failure-free treatment period was 57 days and cov-
ered a substantial part of the median survival of 78 days in the responding patients. In 
advanced cancer patients with serious unstable cancer-related pain refractory to other 
opioids, continuous subcutaneous administration of hydromorphone often results in a 
long-lasting adequate pain control and should be considered even after extensive pre-
treatment with opioids. 
CONCLUSIONS 
This thesis shows more insight in both patient-related and professional-related barriers 
regarding cancer-related pain and pain management, and the scientifi c evidence of 
possible interventions to overcome these barriers. This thesis has the following aims:
1.  To evaluate the prevalence of cancer-related pain and quality of cancer-related pain 
treatment at our outpatient clinic.
 The prevalence of cancer-related pain at the outpatient clinic in our hospital was 
lower than described in the literature, but still over a quarter of the cancer patients 
at the outpatient clinic had pain, and in more than half of them, pain was not ad-
equately treated. 
2. To identify and summarize the available information on barriers hindering adequate 
pain management and interventions aiming to overcome these barriers.
 The key patient-related barriers are lack of knowledge about analgesia, poor adher-
ence, and reluctance to complain about their pain. The most important professional-
related barriers are inadequate pain assessment and inadequate knowledge of 
pain management. The identifi ed interventions to diminish these barriers (patient 
education, professional education, pain assessment and pain consultation) did 
not unequivocally demonstrated clinically relevant improvements in patients’ pain 
intensity. 
3. To study methods to measure patients’ adherence to analgesics in cancer patients.
 The feasibility of MEMS vials was compared with medication diaries to measure ad-
herence in cancer patients. The majority of patients were satisfi ed with both MEMS 
and diary. Adherence data assessed by MEMS and diary were comparable. MEMS and 
a medication diary are equally useful for adherence measurement in analgesics. 
4. To evaluate whether an intervention based on the barriers hindering adequate pain 
management will improve patients’ pain intensity and interference in daily life.
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 In an RCT, in which a Pain Consult combined with patient Pain Education Program 
was compared to standard pain treatment, we show that this intervention decreased 
pain intensity and interference by pain in daily life and increased patients’ knowledge 
and adherence to analgesics in oncology outpatients. 
5. To evaluate whether an opioid rotation to parenteral hydromorphone will improve 
patients’ pain intensity in patients with complex pain problems.
 In patients with complex pain problems, who already use opioids in high doses for 
moderate to severe pain, rotating from a certain opioid to parenteral hydromor-
phone often results in long-lasting adequate pain control. 
DISCUSSION
Internationally, the prevalence of cancer-related pain remains high through the years 
3. This is always cited to demonstrate that cancer-related pain is a problem. However, 
is the prevalence the right indicator? The prevalence includes all patients with cancer-
related pain (from almost no pain, NRS=1, till unbearable pain NRS=10), and is not an 
indicator of the adequacy of pain management. It would be more interesting to report 
the percentages of patients with moderate to severe pain, because those patients are 
not treated adequately. 
The subsequent question is what do we mean with moderate to severe pain? What 
should be the cut point on the Numeric Rating Scale? According to the Dutch Adult Can-
cer Pain Guideline the cut point for moderate to severe cancer-related pain is NRS 548. On 
the other hand, the National Comprehensive Cancer Network (NCCN) guideline ‘Adult 
Cancer Pain’ categorized moderate to severe pain as NRS ≥ 449. However, it is unclear if 
one cut point is valid in all situations; diff erent stages of cancer, gender or underlying 
mechanism. We need more evidence, before using such cut points, but agreement on 
defi nitions is eagerly awaited for use in clinical and epidemiologic studies. 
As described in the introduction, adequate pain control is still not achieved in a 
substantial group of patients with cancer-related pain due to the existence of profes-
sional- and patient-related barriers and the complexity of pain problems in a part of the 
patients (Figure 1). Our review confi rmed that both patient-related and professional-
related barrier play an important role in pain management. The RCT in this thesis 
was designed to diminish these barriers. To reduce the infl uence of physician-related 
barriers, patients were referred to a pain specialist. To decrease patient-related barriers, 
patients received a Pain Education Program. However, during this RCT, we met other 
barriers. We were forced to change our study design because of the slow accrual of our 
patients. Possible explanations for the slow accrual were the strict inclusion criteria we 
used and that we were not able to screen all patients by ourselves. Patients’ pain was 
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not always documented. This could be due to known barriers (chapter 3), namely that 
patients were often reluctant to report their pain and physicians assessed patients’ pain 
and pain management inadequately. The RCT show that the combined intervention 
decreased patients’ pain intensity and increased daily functioning. When decreasing the 
barriers, patients’ pain treatment will improve. Therefore, to improve the pain treatment 
at the outpatient clinic, an integrated system should be implemented. Patients’ pain 
intensity should be systematically measured and documented and actively reported 
to the treating professionals. Besides this, an oncology pain protocol should be easily 
accessible for all professionals and referral to a pain specialist and to a pain nurse for 
tailored pain education should be integrated in cancer care for patients with moderate 
to severe cancer pain. 
A third reason why not all patients achieved adequate pain control is that some 
patients have complex pain problems (Introduction, Figure 1). The study in chapter 6 
showed that a rotation to parenteral hydromorphone, as an example of a treatment for 
a group of patients with complex pain, was successful in 83% of the included advanced 
cancer patients with unstable pain refractory to other opioids. Therefore, when pain 
management failed with the more common opioids, a rotation to parenteral hydromor-
phone could be a useful option. 
The interventions in the studies described in this thesis showed an improvement in 
patients’ pain. However, in a part of the patients pain was still not adequately managed. 
At the end of a study, these patients scored their pain as moderate to severe despite the 
changes in pain treatment or education. Some patients made a conscious decision be-
tween pain and side eff ects and decided to tolerate some pain. In other patients, much 
attention had been given to all treatment options but despite all eff orts, prolonged pain 
relief could not be achieved. It is still unclear which factors may infl uence patients’ pain 
and whether it is possible to achieve adequate analgesia in all patients. For individual 
patients, the underlying factors related to benefi cial and detrimental eff ects of specifi c 
opioids are unknown. For optimizing patients’ tailored opioid treatment, insight in un-
derlying pharmacodynamic mechanisms is eagerly awaited. Besides this, it is possible 
that the currently available analgesics are not suffi  ciently eff ective and that novel treat-
ment options with other physical targets are necessary.
This leads to the following recommendations:
1. More research is necessary to know which scores on a 0-10 Numeric Rating Scale 
represent moderate to severe pain.
2. To improve patients’ pain management at the outpatient clinic, an integrated system 
should be implemented, concerning systematic pain measurement; pain protocol, 
including guideline for referral to a pain specialist; and referral to a pain nurse for 
tailored instruction how to cope with their pain and their analgesics. 
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3. In palliative care priority should be given to stimulate research on pharmacodynamic 
and pharmacokinetic mechanisms of the WHO analgesics; furthermore, research on 
novel therapies may be eagerly awaited.
Wendy Oldenmenger bw.indd   114 08-11-11   10:33
Summary and discussion 115
REFERENCES
 1. Coebergh JWW, Van de Poll-Dranse LV, Alers JC, et al: Kanker in Nederland. Trends, prognoses en 
implicaties voor zorgvraag. Amsterdam, KWF, 2004
 2. www.iknl.nl, 2011
 3. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al: Prevalence of pain in patients 
with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437-49, 2007
 4. Jadad AR, Browman GP: The WHO analgesic ladder for cancer pain management. Stepping up the 
quality of its evaluation. Jama 274:1870-3, 1995
 5. Azevedo Sao Leao Ferreira K, Kimura M, Jacobsen Teixeira M: The WHO analgesic ladder for cancer 
pain control, twenty years of use. How much pain relief does one get from using it? Support Care 
Cancer 14:1086-93, 2006
 6. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med 
Singapore 23:129-38, 1994
 7. Cleeland CS, Gonin R, Hatfi eld AK, et al: Pain and its treatment in outpatients with metastatic 
cancer. N Engl J Med 330:592-6, 1994
 8. Yates P, Edwards H, Nash R, et al: A randomized controlled trial of a nurse-administered educa-
tional intervention for improving cancer pain management in ambulatory settings. Patient Educ 
Couns 53:227-37, 2004
 9. Bostrom B, Sandh M, Lundberg D, et al: Cancer-related pain in palliative care: patients’ percep-
tions of pain management. J Adv Nurs 45:410-9, 2004
 10. Ward SE, Goldberg N, Miller-McCauley V, et al: Patient-related barriers to management of cancer 
pain. Pain 52:319-24, 1993
 11. Wills BS, Wootton YS: Concerns and misconceptions about pain among Hong Kong Chinese 
patients with cancer. Cancer Nurs 22:408-13, 1999
 12. Lin CC, Ward SE: Patient-related barriers to cancer pain management in Taiwan. Cancer Nurs 
18:16-22, 1995
 13. Lin CC: Barriers to the analgesic management of cancer pain: a comparison of attitudes of Taiwan-
ese patients and their family caregivers. Pain 88:7-14, 2000
 14. Chung TK, French P, Chan S: Patient-related barriers to cancer pain management in a palliative 
care setting in Hong Kong. Cancer Nurs 22:196-203, 1999
 15. Wang KY, Ho ST, Ger LP, et al: Patient barriers to cancer pain management: from the viewpoint of 
the cancer patients receiving analgesics in a teaching hospital of Taiwan. Acta Anaesthesiol Sin 
35:201-8, 1997
 16. Ward SE, Hernandez L: Patient-related barriers to management of cancer pain in Puerto Rico. Pain 
58:233-8, 1994
 17. Ward S, Misiewicz H: Concerns About Analgesics Among Patients and Family Caregivers in a 
Hospice Setting. Research in Nursing & Health 19:205-211, 1996
 18. Ward S, Gatwood J: Concerns about reporting pain and using analgesics. A comparison of per-
sons with and without cancer. Cancer Nurs 17:200-6, 1994
 19. Ger LP, Ho ST, Wang JJ: Physicians’ knowledge and attitudes toward the use of analgesics for 
cancer pain management: a survey of two medical centers in Taiwan. J Pain Symptom Manage 
20:335-44, 2000
 20. Yu S, Wang XS, Cheng Y, et al: Special aspects of cancer pain management in a Chinese general 
hospital. Eur J Pain 5 Suppl A:15-20, 2001
Wendy Oldenmenger bw.indd   115 08-11-11   10:33
116 Chapter 7
 21. Anderson KO, Mendoza TR, Valero V, et al: Minority cancer patients and their providers: pain 
management attitudes and practice. Cancer 88:1929-38, 2000
 22. Sapir R, Catane R, Strauss-Liviatan N, et al: Cancer pain: knowledge and attitudes of physicians in 
Israel. J Pain Symptom Manage 17:266-76, 1999
 23. O’Brien S, Dalton JA, Konsler G, et al: The knowledge and attitudes of experience oncology nurses 
regarding the management of cancer-related pain. Oncol Nurs Forum 23:515-21, 1996
 24. Von Roenn JH, Cleeland CS, Gonin R, et al: Physician attitudes and practice in cancer pain man-
agement. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119:121-6, 
1993
 25. Vortherms R, Ryan P, Ward S: Knowledge of, attitudes toward, and barriers to pharmacologic 
management of cancer pain in a statewide random sample of nurses. Res Nurs Health 15:459-66, 
1992
 26. Camp-Sorrell D, O’Sullivan P: Eff ects of continuing education. Pain assessment and documenta-
tion. Cancer Nurs 14:49-54, 1991
 27. Vallerand AH, Riley-Doucet C, Hasenau SM, et al: Improving cancer pain management by homec-
are nurses. Oncol Nurs Forum 31:809-16, 2004
 28. Kravitz RL, Delafi eld JP, Hays RD, et al: Bedside charting of pain levels in hospitalized patients with 
cancer: a randomized controlled trial. J Pain Symptom Manage 11:81-7, 1996
 29. Trowbridge R, Dugan W, Jay SJ, et al: Determining the eff ectiveness of a clinical-practice interven-
tion in improving the control of pain in outpatients with cancer. Acad Med 72:798-800, 1997
 30. Cleeland CS, Portenoy RK, Rue M, et al: Does an oral analgesic protocol improve pain control 
for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology 
Group. Ann Oncol 16:972-80, 2005
 31. Du Pen SL, Du Pen AR, Polissar N, et al: Implementing guidelines for cancer pain management: 
results of a randomized controlled clinical trial. J Clin Oncol 17:361-70, 1999
 32. Rimer B, Levy MH, Keintz MK, et al: Enhancing cancer pain control regimens through patient 
education. Patient Educ Couns 10:267-77, 1987
 33. Chang MC, Chang YC, Chiou JF, et al: Overcoming patient-related barriers to cancer pain manage-
ment for home care patients. A pilot study. Cancer Nurs 25:470-6, 2002
 34. Oliver JW, Kravitz RL, Kaplan SH, et al: Individualized patient education and coaching to improve 
pain control among cancer outpatients. J Clin Oncol 19:2206-12, 2001
 35. Miaskowski C, Dodd M, West C, et al: Randomized clinical trial of the eff ectiveness of a self-care 
intervention to improve cancer pain management. J Clin Oncol 22:1713-20, 2004
 36. Dalton J: Education for pain management: a pilot study. Patient Education and Counseling 9:155-
165, 1987
 37. Anderson KO, Mendoza TR, Payne R, et al: Pain education for underserved minority cancer pa-
tients: a randomized controlled trial. J Clin Oncol 22:4918-25, 2004
 38. Lin CC, Chou PL, Wu SL, et al: Long-term eff ectiveness of a patient and family pain education 
program on overcoming barriers to management of cancer pain. Pain 122:271-81, 2006
 39. Lai YH, Guo SL, Keefe FJ, et al: Eff ects of brief pain education on hospitalized cancer patients with 
moderate to severe pain. Support Care Cancer 12:645-52, 2004
 40. Ward S, Donovan HS, Owen B, et al: An individualized intervention to overcome patient-related 
barriers to pain management in women with gynecologic cancers. Res Nurs Health 23:393-405, 
2000
 41. de Wit R, van Dam F, Zandbelt L, et al: A pain education program for chronic cancer pain patients: 
follow-up results from a randomized controlled trial. Pain 73:55-69, 1997
Wendy Oldenmenger bw.indd   116 08-11-11   10:33
Summary and discussion 117
 42. Chesney MA: Factors aff ecting adherence to antiretroviral therapy. Clin Infect Dis 30 Suppl 
2:S171-6, 2000
 43. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens 
and medication compliance. Clin Ther 23:1296-310, 2001
 44. Rand CS, Wise RA: Measuring adherence to asthma medication regimens. Am J Respir Crit Care 
Med 149:S69-76; discussion S77-8, 1994
 45. Stone AA, Shiff man S, Schwartz JE, et al: Patient compliance with paper and electronic diaries. 
Control Clin Trials 24:182-99, 2003
 46. Murray A, Hagen NA: Hydromorphone. J Pain Symptom Manage 29:S57-66, 2005
 47. Quigley C: Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev:CD003447, 
2002
 48. CBO, VIKC: Diagnostiek en behandeling van pijn bij patiënten met kanker. Alphen a/d/ Rijn, Van 
Zuiden Communications B.V., 2008
 49. Swarm R, Abernethy AP, Anghelescu DL, et al: Adult Cancer Pain, NCCN Clinical Practice Guide-
lines in Oncology, National Comprehensive Cancer Network, 2011
Wendy Oldenmenger bw.indd   117 08-11-11   10:33
Wendy Oldenmenger bw.indd   118 08-11-11   10:33
APPENDIX
Sam envatting en discussie
Wendy Oldenmenger bw.indd   119 08-11-11   10:33
120 Appendix
Sinds 1990 is de prevalentie van kanker in Nederland toegenomen met 3 – 3.5% per jaar. 
Deze toename werd vooral veroorzaakt door een bevolkingstoename, in het bijzonder 
van de ouderen. In 2010 leefden er in Nederland 540 371 mensen met kanker (20-jaars 
prevalentie)1-2. Voor patiënten met kanker is pijn één van de meest voorkomende en ge-
vreesde symptomen. De prevalentie van kankergerelateerde pijn is door de jaren heen 
stabiel gebleven; ongeveer 53% van de patiënten met kanker ervaart pijn tijdens hun 
ziekte3 (hoofdstuk 1). Het doel van de pijnbehandeling is om de mate waarin patiënten 
pijn hebben te verminderen tot een draaglijk niveau met acceptabele bijwerkingen.
De behandeling van kankergerelateerde pijn bestaat, zo mogelijk, uit een combinatie 
van een antitumor behandeling (behandeling die de oorzaak van de pijn aanpakt, 
bijv. radiotherapie bij botmetastasen) en een symptomatische behandeling met 
pijnstillers. Hoewel de Wereld Gezondheidsorganisatie (WHO) in 1986 een pijnladder 
introduceerde, kan, tot de dag van vandaag, maar ongeveer 76% (range 45% - 100%) 
van de patiënten met pijn bij kanker, adequaat behandeld worden voor hun pijn4-5. 
Mogelijke redenen voor deze inadequate pijnbehandeling zijn de complexiteit van de 
pijnproblemen bij een substantieel deel van de patiënten met kanker en het bestaan 
van diverse misverstanden en vooroordelen met betrekking tot pijn en pijnbehandeling 
bij zowel zorgverleners als patiënten. Daarom blijft aandacht voor verbetering van de 
pijnbehandeling nodig (hoofdstuk 1, Figuur 1).
Omdat de prevalentie van kankergerelateerde pijn varieerde tussen de diverse studies, 
hebben wij een onderzoek uitgevoerd op de polikliniek van het Erasmus MC Daniel den 
Hoed ter bepaling van de prevalentie van kankergerelateerde pijn; daarbij werd beoor-
deeld hoe vaak een adequate pijnbehandeling was voorgeschreven. Hoofdstuk 2 geeft 
de resultaten weer van de prevalentie meting bij 915 volwassen poliklinische patiënten 
met kanker. Patiënten werden gevraagd hun pijn aan te geven op een 11-punts nume-
rieke beoordelingsschaal (NRS) van 0 (geen pijn) tot 10 (ergst denkbare pijn)6. In totaal 
gaven 246 van de 915 patiënten (27%) aan dat zij de afgelopen week pijn hadden gehad 
WHO Richtlijn voor 
kankergerelateerde 
pijnbehandeling 
Effectief in 45% - 100% 
Complexe pijn problemen: 
- neuropathische pijn 
- doorbraak pijn 
- morfine is niet altijd voldoende 
Belemmeringen van hulpverleners: 
- niet volgen van richtlijnen voor pijn bij      
  kanker 
- angst voor opioïden 
- gebrek aan aandacht voor pijn 
Belemmeringen van patiënten: 
- angst voor opioïden 
- medicatie ontrouw 
- weigering om pijn te rapporteren 
Figuur 1. Redenen voor inadequate pijnbehandeling.
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of pijnmedicatie hadden gebruikt. Van deze patiënten hadden 180 patiënten (73%) een 
voorschrift voor pijnmedicatie. Van de patiënten met een voorschrift voor pijnmedicatie 
had 70% een voorschrift voor medicatie op vaste tijden (‘around the clock’ (ATC)). Daar-
naast had 58% ‘zo nodig’ pijnmedicatie voorgeschreven gekregen. Voor 158 van de 244 
patiënten (65%) was de pijnbehandeling inadequaat7. In totaal hadden 125 patiënten 
een voorschrift voor pijnmedicatie op vaste tijden en waren daarmee evalueerbaar voor 
een meting van medicatietrouw. Medicatietrouw werd berekend voor de ATC-medicatie 
en werd als inadequaat beschouwd indien minder dan 100% van de voorgeschreven 
dosering ingenomen werd. Eén en negentig patiënten (73%) met een voorschrift voor 
ATC-medicatie waren medicatietrouw. Wij konden in deze studie niet bepalen waarom 
patiënten hun pijnmedicatie niet innamen en waarom zorgverleners niet het meest 
optimale voorschrift voor pijnmedicatie gaven. Daarom beschrijft hoofdstuk 3 een 
systematisch overzicht van de literatuur over de belangrijkste barrières die een ade-
quate pijnbehandeling bij patiënten met kanker verhinderen en over de interventies 
die bedoeld zijn om deze barrières te verminderen. 
Patiënten belemmeren hun eigen pijnbehandeling door de vooroordelen die zij 
hebben over pijnmedicatie en bijwerkingen (bijv. angst voor verslaving), onvoldoende 
medicatietrouw aan de voorgeschreven pijnmedicatie, slechte communicatie met 
zorgverleners over de ervaren pijn en bezorgdheid over pijn (bijv. angst dat toename 
van pijn progressie van ziekte betekent)8-18. Zorgverleners, zowel artsen als verpleeg-
kundigen, geven als belangrijkste barrières aan: inadequate beoordeling van de pijn 
en pijnbehandeling, terughoudendheid van patiënten om pijn aan te geven of de pijn 
in een cijfer uit te drukken, en onvoldoende kennis van pijn en pijnbehandeling bij 
zorgverleners (bijv. morfi ne heeft een maximale dosering)19-25. In dit review wordt een 
overzicht gegeven van de in de literatuur beschreven interventies die als doel hebben 
de barrières te verminderen: patiënteneducatie, educatie van zorgverleners, pijnmeting 
en een pijn consult. Deze interventies zijn slechts afzonderlijk bestudeerd en nooit 
gecombineerd in multidisciplinaire studies. Studies over educatie aan zorgverleners en 
over systematische pijnmeting rapporteerden geen patiëntgerelateerde uitkomstmaten 
(bijv. pijnintensiteit)26-29. In vijf van de elf gerandomiseerde studies (RCTs) over patiën-
teneducatie (‘Pijn Educatie Programma’ (PEP)) en in de twee RCTs over pijn consulten, 
nam de mate waarin patiënten pijn hadden statistisch signifi cant af. Echter er werd geen 
verandering gezien in de adequaatheid van de pijnbehandeling, de medicatietrouw of 
de invloed van de pijn op het dagelijks functioneren8,30-41. De studies verschilden sterk 
van elkaar wat betreft het aantal bestudeerde patiënten en de duur van de follow-up. 
De steekproefgrootte van deze studies verschilde zeer en de follow-up van patiënten 
was per studie anders (5 dagen tot 8 weken). Daarnaast werden in de RCTs verschillende 
maten gebruikt om pijnintensiteit te meten (bijv. pijn op dit moment of ergste pijn). 
Ook is het mogelijk dat de resultaten van studies over patiënteneducatie gefl atteerd 
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zijn, omdat enkele van deze studies niet alle verschillende typen pijnintensiteiten rap-
porteerden die wel gemeten waren.
Eén van de factoren die de adequaatheid van de pijnbehandeling kan beïnvloeden 
is de mate van medicatietrouw aan de voorgeschreven pijnmedicatie. Bij kankergere-
lateerde pijn wordt medicatietrouw meestal gemeten met behulp van zelfrapportage. 
Dit wordt echter beperkt door het geheugen van de patiënt. Bovendien is bekend dat 
een medicatiedagboek wisselend wordt ingevuld en patiënten de neiging hebben deze 
achteraf in te vullen42-45. Een andere indirecte methode om medicatietrouw te meten is 
het Medication Event Monitoring System (MEMS). Een MEMS potje is een standaard me-
dicatiepotje met een deksel dat een microprocessor bevat die de exacte tijd en datum 
van elke opening registreert. Net zoals bij andere indirecte metingen van medicatie-
trouw, is het met de MEMS onmogelijk om te bepalen of de medicatie ook daadwerkelijk 
ingenomen is43. MEMS was nog niet eerder gebruikt voor het meten van pijnmedicatie. 
In hoofdstuk 4 bepalen wij de bruikbaarheid van MEMS potjes in vergelijking met 
medicatiedagboeken in patiënten met kanker met chronische pijn die één of meerdere 
voorschriften voor pijnmedicatie hebben. 
Gedurende vier weken gebruikten 46 patiënten met kankergerelateerde pijn MEMS 
potjes voor hun pijnmedicatie en registreerden zij de ingenomen pijnmedicatie in een 
medicatiedagboek. MEMS werd door 79% van deze patiënten gedurende de gehele 
studieperiode gebruikt; 70% gebruikte het medicatiedagboek gedurende deze vier we-
ken. Het merendeel van de patiënten was tevreden met zowel MEMS als het dagboek. 
De mate van medicatietrouw gemeten door middel van MEMS en het dagboek was 
vergelijkbaar. Een subgroep analyse bij patiënten met één of met meerdere pijnstillers 
gaf vergelijkbare resultaten voor beide methoden. MEMS en een medicatiedagboek zijn 
dus even bruikbaar voor medicatietrouw meting bij pijnmedicatie. 
Om de pijnbehandeling van patiënten te verbeteren, hebben wij een multidisciplinaire 
en multilevel gerandomiseerde gecontroleerde studie uitgevoerd. Zoals in hoofdstuk 3 
is aangegeven, zijn interventies om de barrières bij zowel zorgverleners als patiënten 
te verminderen altijd afzonderlijk onderzocht en nooit gecombineerd. De resultaten 
van deze interventies op het verbeteren van de pijnintensiteit wisselde sterk tussen de 
verschillende studies. In hoofdstuk 5 worden de resultaten van een RCT weergegeven. 
In deze RCT werd de eff ectiviteit onderzocht van een pijnconsult gecombineerd met 
patiënteneducatie over pijn. Het belangrijkste eindpunt van deze studie was de overall 
afname van de gemiddelde pijnintensiteit over de studieperiode van 8 weken, in verge-
lijking met de startwaarde. 
Patiënten werden in eerste instantie gerandomiseerd tussen (1) standaard pijnbehan-
deling (SC), (2) pijnconsult (PC), of (3) pijnconsult gecombineerd met een pijneducatie 
programma voor patiënten (PC&PEP). Tijdens het pijnconsult bepaalde de pijnarts of 
de oorzaak van de pijn duidelijk was; gaf advies over de antitumor behandeling en 
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optimaliseerde zo nodig de medicamenteuze pijnbehandeling. PEP bestaat uit pati-
enteneducatie ‘op maat’ om de kennis van patiënten over pijn en pijnbehandeling te 
verbeteren en om patiënten te stimuleren tijdig zelf hulp te zoeken bij pijnklachten. 
Daarnaast werden deze patiënten wekelijks gebeld om na te vragen hoe het ging met 
de pijn en de bijwerkingen41. In januari 2009 werd duidelijk dat deze 3-armige studie niet 
haalbaar was omdat de patiënteninclusie te traag verliep. Vanaf dat moment werden 
patiënten gerandomiseerd tussen (1) SC en (3) PC&PEP. In totaal werden er uiteindelijk 
37 patiënten gerandomiseerd in de SC groep en 35 patiënten in de PC&PEP groep. De 
overall afname van de pijnintensiteit en de invloed van pijn op het dagelijks functione-
ren was signifi cant groter in de groep patiënten die gerandomiseerd waren voor PC&PEP 
dan voor SC (gemiddelde pijn 31% vs. 20%, p=0.03; pijn op dit moment 30% vs. 16%, 
p=0.016; invloed van pijn op het dagelijks functioneren 20% vs. 2.5%, p=0.01). De ade-
quaatheid van de pijnbehandeling was niet verschillend tussen de groepen. Echter het 
percentage patiënten met zowel een ATC- als een zo nodig- voorschrift voor opioïden 
nam in de PC&PEP groep toe van 48% bij start tot 88% na acht weken. In de SC groep 
bleef dit percentage stabiel op 50%. Het verschil tussen de twee groepen was statistisch 
signifi cant na acht weken (p=0.003). Patiënten waren na 8 weken meer medicatietrouw 
wanneer zij gerandomiseerd waren voor PC&PEP dan voor SC (p=0.03). Na twee weken 
was de pijnkennis signifi cant beter bij de patiënten in de PC&PEP groep dan in de SC 
groep (p=0.002). Concluderend, PC&PEP verbeterde de pijnintensiteit, invloed van pijn 
op dagelijks functioneren, medicatietrouw en pijnkennis van poliklinische patiënten 
met kankergerelateerde pijn. Deze studie was de eerste die een eff ect op het dagelijks 
functioneren aantoonde. 
Zoals beschreven in de introductie en in fi guur 1, is de complexiteit van het pijnpro-
bleem bij sommige patiënten een andere reden waarom de pijnbehandeling niet altijd 
eff ectief is. In ons ziekenhuis kunnen patiënten die ondraaglijke bijwerkingen hebben 
van morfi ne of fentanyl, en patiënten met aanhoudende pijn ondanks meerdere do-
sisverhogingen, een opioid rotatie krijgen naar parenteraal toegediende hydromorfon. 
Hydromorfon is een semi-synthetische derivaat van morfi ne, met vergelijkbare werking 
en bijwerkingen als morfi ne. Hydromorfon kan subcutaan gegeven worden in hoge 
doseringen46-47. Hoofdstuk 6 beschrijft een studie waarin de pijnstillende werking en 
bijwerkingen van hydromorfon onderzocht werden bij patiënten met gemetastaseerde 
ziekte die ernstige kankergerelateerde pijn hadden. De redenen voor rotatie naar 
parenterale hydromofon waren inadequate pijnstilling met of zonder te verwachten 
toedieningproblemen als gevolg van hoge doseringen opioïden (n=61) en ondraaglijke 
bijwerkingen op andere opioïden met aanhoudende pijn (n=43). Voor deze rotatie was 
88% van deze patiënten al behandeld met twee of meerdere opioïd rotaties. Adequate 
pijnstilling werd bereikt bij 86 patiënten (83%) binnen een mediaan van 5 dagen. Acht 
van deze 86 patiënten hadden nog steeds bijwerkingen echter deze waren acceptabel. 
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De gemiddelde pijnintensiteit in rust nam af van 5.4 (standaard deviatie (sd)=2.1) tot 2.4 
(sd=1.5, p<0.001) op een 0-10 NRS. De mediane behandelperiode met hydromorfon was 
57 dagen, een substantieel deel van de mediane overleving de responderende patiënten 
(78 dagen). Bij patiënten met gemetastaseerde ziekte die ernstige kankergerelateerde 
pijn hadden die niet reageerde op andere opioïden, gaf continue toediening van subcu-
tane hydromorfon een langdurende pijncontrole. Daarom zou subcutaan toegediende 
hydromorfon overwogen moeten worden bij patiënten met moeilijk te behandelen pijn, 
zelfs bij patiënten die al uitgebreid zijn voorbehandeld met opioïden.
CONCLUSIES
Dit proefschrift geeft meer inzicht in zowel patiëntgerelateerde en zorgverlenergerela-
teerde barrières die een optimale pijnbehandeling verhinderen, en geeft inzicht in het 
wetenschappelijke bewijs van mogelijke interventies om deze barrières te verminderen. 
Dit proefschrift heeft de volgende doelstellingen:
1. Het evalueren van de prevalentie van kankergerelateerde pijn en de kwaliteit van de 
pijnbehandeling op onze polikliniek
 De prevalentie van kankergerelateerde pijn op de polikliniek in ons ziekenhuis was 
lager dan beschreven in de literatuur. Toch had nog steeds ruim een kwart van de 
patiënten met kanker op onze polikliniek pijn, en in meer dan de helft van deze 
patiënten werd de pijn niet adequaat behandeld.
2. Het identifi ceren en samenvatten van de beschikbare informatie betreff ende barrières 
die adequate pijnbehandeling belemmeren, en van interventies om deze barrières te 
verminderen.
 De belangrijkste patiëntgerelateerde barrières zijn gebrek aan kennis over pijnme-
dicatie, slechte medicatietrouw, en terughoudendheid om de pijn bespreekbaar te 
maken. De belangrijkste zorgverlenergerelateerde barrières zijn inadequate beoor-
deling van de pijn en inadequate kennis over pijnbehandeling. De studies over de 
geïdentifi ceerde interventies om deze barrières te verminderen (patiënteneducatie, 
educatie aan zorgverleners, pijnmeting en pijnconsultatie) toonden niet eenduidig 
een klinisch relevante verbetering van de mate waarin patiënten pijn hebben aan. 
3. Bestuderen van methoden om medicatietrouw aan pijnmedicatie te meten bij patiënten 
met kanker.
 De bruikbaarheid van MEMS medicatiepotjes werd vergeleken met medicatiedag-
boeken om medicatietrouw te meten aan pijnmedicatie bij patiënten met kanker. De 
meerderheid van de patiënten was tevreden met zowel MEMS als dagboek. De mate 
van medicatietrouw gemeten door middel van MEMS en het dagboek was vergelijk-
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baar. MEMS en een medicatiedagboek zijn dus even bruikbaar voor medicatietrouw 
meting bij pijnmedicatie. 
4. Beoordelen of een interventie, die gebaseerd is op de barrières die adequate pijnbehan-
deling belemmeren, leidt tot een overall afname van de mate waarin patiënten pijn 
hebben en de invloed van pijn op het dagelijks functioneren. 
 In een RCT, waarin een pijnconsult gecombineerd met patiënteneducatie werd ver-
geleken met de standaard pijnbehandeling bij poliklinische patiënten met kanker, 
konden wij aantonen dat deze interventie de pijnintensiteit en de invloed van pijn 
op het dagelijks functioneren verminderd, en daarnaast de pijnkennis van patiënten 
en de medicatietrouw verbeterd bij poliklinische patiënten met pijn bij kanker.
5. Het evalueren of een opioïd rotatie naar parenteraal toegediende hydromorfon de mate 
waarin patiënten pijn hebben, vermindert bij patiënten met complexe pijnproblemen.
 Bij patiënten met complexe pijnproblemen, die al hoge doseringen opioïden ge-
bruikten voor matige tot ernstige pijn, gaf rotatie van een opioïd naar parenteraal 
toegediende hydromorfon vaak een langdurige adequate pijnstilling. 
DISCUSSIE
De prevalentie van kankergerelateerde pijn blijft hoog door de jaren heen3. Dit wordt al-
tijd beschreven om aan te geven dat kankergerelateerde pijn nog steeds een probleem 
is. Echter, het is de vraag of de prevalentie wel een juiste indicator hiervoor is. De preva-
lentie houdt alle patiënten in met kankergerelateerde pijn, van bijna geen pijn, NRS=1, 
tot ondraaglijke pijn, NRS=10, en is daarmee geen indicator voor de adequaatheid van 
de pijnbehandeling. Het zou veel interessanter zijn om het percentage patiënten met 
matig tot ernstige pijn weer te geven, omdat deze patiënten niet goed behandeld 
worden voor hun pijn. 
Echter, de daarop volgende vraag is, wat bedoelen wij met matig tot ernstige pijn? 
Wat is dan het juiste afkappunt op een numerieke beoordelingsschaal? Volgens de 
Nederlandse richtlijn ‘Diagnostiek en behandeling van pijn bij patiënten met kanker’ 
is het afkappunt voor matig tot ernstige kankergerelateerde pijn NRS 548. Echter de 
‘National Comprehensive Cancer Network’ (NCCN) categoriseert in haar richtlijn ‘Adult 
Cancer Pain’, matig tot ernstige pain als NRS ≥ 449. Het is echter onduidelijk of één afkap-
punt geldig is voor alle situaties; voor de verschillende stadia van kanker, geslacht of 
onderliggend mechanisme. We hebben meer onderzoek nodig voordat afkappunten 
in de praktijk gebruikt kunnen worden, echter overeenstemming over de defi nities is 
noodzakelijk voor het gebruik in klinische en epidemiologische studies. 
Zoals in de introductie en in bovenstaande fi guur beschreven wordt, kan adequate 
controle niet altijd behaald worden in een substantieel deel van de patiënten met 
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kankergerelateerde pijn. Dit wordt mogelijk veroorzaakt door misverstanden en 
vooroordelen van zowel patiënten als zorgverleners en door de complexiteit van de 
pijnproblemen bij een deel van de patiënten (Figuur 1). Ons review bevestigt dat zowel 
patiëntgerelateerde als zorgverlenergerelateerde barrières een belangrijke rol spelen in 
de pijnbehandeling. De RCT die in dit proefschrift beschreven wordt, was ontworpen 
of deze barrières te verminderen. Om de invloed van de barrières van zorgverleners 
te verminderen, werden patiënt verwezen naar een pijnspecialist. Om de patiëntge-
relateerde barrières te verminderen, kregen patiënten een pijneducatie programma 
aangeboden. Echter gedurende deze studie, liepen wij tegen andere barrières aan. We 
moesten ons studiedesign veranderen omdat de patiënteninclusie zeer traag verliep. 
Mogelijke verklaringen voor deze trage inclusie kunnen de strikte inclusiecriteria zijn 
die wij hanteerden en daarnaast dat wij niet alle patiënten zelf op pijn konden screenen. 
Of patiënten pijn hadden, was niet altijd gedocumenteerd. Dit kan veroorzaakt zijn 
door diverse bekende barrières (hoofdstuk 3), namelijk dat patiënten vaak terughou-
dend waren om aan te geven dat ze pijn hadden en daarnaast dat artsen de pijn en 
pijnbehandeling van patiënten niet adequaat beoordeelden. Deze RCT maakt duidelijk 
dat de gecombineerde interventie de mate waarin patiënten pijn hebben verminderd 
en het dagelijks functioneren verbeterd. Wanneer de barrières verminderd worden, 
verbeterd de pijnbehandeling van patiënten. Daarom, om de pijnbehandeling op de 
polikliniek te kunnen verbeteren, zou een geïntegreerd systeem geïmplementeerd 
moeten worden. De pijn van patiënten zou systematisch gemeten en gedocumenteerd 
moeten worden en direct aan de zorgverleners teruggeven moeten worden. Daarnaast 
zou een oncologisch pijnprotocol toegankelijk moeten zijn voor alle zorgverleners en 
een verwijzing naar een pijnspecialist en naar een pijnverpleegkundige voor ‘op maat’ 
patiënteneducatie over pijn zou in de oncologische zorg geïntegreerd moeten zijn voor 
alle patiënten met matig tot ernstige pijn. 
Een derde reden waarom niet alle patiënten adequaat behandeld worden voor hun 
pijn is dat sommige patiënten complexe pijnproblemen hebben (Introductie, Figuur 1). 
De studie die beschreven wordt in hoofdstuk 6 laat zien dat een rotatie naar parenteraal 
toegediende hydromorfon, als een voorbeeld van een behandeling voor een groep 
patiënten met complexe pijn, succesvol was in 83% van de geïncludeerde kankerpati-
enten met gemetastaseerde ziekte die onstabiele pijncontrole hadden, niet reagerend 
op andere opioïden. Daarom, wanneer de pijnbehandeling niet eff ectief is met de meer 
gebruikelijke opioïden, kan een rotatie naar parenteraal toegediende hydromorfon een 
goede optie zijn. 
De interventies in de studies beschreven in dit proefschrift laten een verbetering zien 
van de pijn van patiënten. Echter, bij een deel van de patiënten werd de pijn nog steeds 
niet adequaat behandeld. Aan het einde van de studie scoorden deze patiënten hun pijn 
nog steeds als matig tot ernstig ondanks de veranderingen in de pijnbehandeling of de 
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patiënteneducatie. Sommige patiënten maakten een bewuste afweging tussen pijn en 
bijwerkingen en besloten om wat meer pijn te accepteren. Bij andere patiënten is er 
veel aandacht geweest voor alle mogelijke behandelingen maar ondanks alle moeite 
kon er geen langdurige pijnstilling bereikt worden. Het is nog steeds onduidelijk welke 
factoren de pijn van patiënten mogelijk beïnvloedt en in hoeverre het mogelijk is om 
adequate pijnstilling te bereiken in alle patiënten. Voor individuele patiënten zijn de 
onderliggende factoren die gerelateerd zijn aan zowel gunstige als ongunstige eff ecten 
van specifi eke opioïden onbekend. Voor het optimaliseren van een ‘op maat’ gemaakte 
pijnbehandeling met opioïden is inzicht in de onderliggende farmacodynamische en 
farmacokinetische mechanismen noodzakelijk. Daarnaast is het mogelijk dat de mo-
menteel beschikbare analgetica niet voldoende eff ectief zijn en dat nieuwe middelen 
die andere aangrijpingspunten in het lichaam hebben nodig zijn om de pijnbehande-
ling te verbeteren. 
Dit leidt tot de volgende aanbevelingen:
1. Meer onderzoek is nodig om te weten welke scores op de 0-10 numerieke beoorde-
lingsschaal matig tot ernstige pijn weergeven. 
2. Om de poliklinische pijnbehandeling te verbeteren, moet een geïntegreerd systeem 
geïmplementeerd worden, betreff ende systematische pijnmeting; een oncologisch 
pijnprotocol, inclusief richtlijnen voor verwijzing naar een pijnspecialist en ver-
wijzing naar een pijnverpleegkundige voor ‘op maat’ voorlichting hoe met pijn en 
pijnmedicatie om te gaan.
3. In de palliatieve zorg zou meer prioriteit gegeven moeten worden om onderzoek 
naar farmacodynamische en farmacokinetische mechanismen van de WHO analge-
tica te stimuleren; bovendien is onderzoek naar nieuwe therapieën nodig.
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Na een lange periode is het eindelijk zover. Ik heb met veel plezier gewerkt aan het 
onderzoek beschreven in dit proefschrift. Soms ging het goed, soms zat het wat tegen. 
Zonder hulp van velen was dit proefschrift er niet geweest. Ondanks dat ik geprobeerd 
heb iedereen te noemen, ben ik mogelijk toch een aantal mensen vergeten. Mijn excu-
ses hiervoor. 
Allereerst mijn promotor, prof.dr. C.C.D. van der Rijt. Beste Karin, bedankt voor je vertrou-
wen in mij, je bent ook maar opeens met mij opgezadeld. Jij hebt de bijzondere rol op 
je genomen van zowel copromotor en promotor. Bedankt voor het kritische nadenken, 
de zorgvuldige beoordeling van de artikelen en de zeer snelle reacties van de laatste 
documenten van mijn proefschrift. Samen hebben we geen anderen nodig.
Prof.dr. P.A.E. Sillevis Smitt, Prof.dr. F.J.P.M. Huygen en Prof.dr. K.C.P. Vissers wil ik harte-
lijk danken voor hun bereidheid zitting te nemen in de kleine commissie; het manuscript 
door te lezen en te beoordelen.
Ook de overige commissieleden, Prof.dr. J. Verweij, Prof.dr. W.W.A. Zuurmond, dr. 
M. van Dijk en dr. R.H. Enting, wil ik hartelijk danken voor hun aanwezigheid bij mijn 
promotie. 
Prof.dr. P.A.E. Sillevis Smitt. Beste Peter, bedankt voor mijn opleiding in de kankerge-
relateerde pijn binnen de afdeling neuro-oncologie van de Daniel. Ik heb hier de kans 
gekregen voorzichtig te snuff elen aan het klinisch onderzoek, maar nog veel meer 
geleerd wat de praktijk is van pijn bij patiënten met kanker. 
Dr. R.H. Enting, beste Roelien, samen zijn wij gestart bij de afdeling neuro-oncologie 
voor de pijn. Van jou heb ik veel geleerd over de patiëntenzorg bij patiënten met pijn, het 
onderzoek, de eerste publicaties, maar zeker ook de gezellige momenten. Het moest zo 
zijn dat wij ook tegelijkertijd afscheid namen bij de afdeling. Jij naar Groningen, ik naar 
de afdeling interne oncologie. Fijn dat je vandaag plaats wilt nemen in de commissie.
Mijn paranimfen: Arno en Johan. Bedankt dat jullie mij willen begeleiden op dit span-
nende moment. Johan, zie het maar als een eerste stap naar je eigen feestje (over een 
jaar?). Arno, wij zien elkaar niet vaak, jij wonend in Duitsland, ik in Rotterdam. Ik ben 
trots op het feit dat je op deze dag als broer naast mij wilt staan. 
Alle collega’s van de afdeling neuro-oncologie wil ik danken voor de fi jne tijd bij de 
afdeling. Speciaal wil ik Prof.dr. M.J. van den Bent, dr. J.E.C. Bromberg, dr. W. Taal en dr. 
J.L.M. Jongen bedanken voor hun blijvende samenwerking en voor uitvoeren van het 
‘pijnconsult’ in de interventiestudie. Een ander speciaal bedankje is voor Erica en Vivian, 
mijn kamergenootjes bij mijn komst in de Daniel. Zonder jullie steun en gezelligheid was 
ik binnen het jaar al vertrokken en nooit zover gekomen. Ria, jij bedankt voor de secreta-
riële ondersteuning en dat ik tot de dag van vandaag met vragen bij je terecht kan.
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Inmiddels is het Pijnkenniscentrum (PKC) verleden tijd, maar de goede herinneringen 
blijven, vooral aan de collega’s. Erica en Ellen, met zijn drieën hebben wij aan de start 
van het Pijnkenniscentrum onder Rianne de Wit gestaan. Rianne, Rhodee, Anneke, 
Dirk, Nanda, George, Annemerle, Tilly, Albertina, Michael en Yvonne bedankt voor de 
samenwerking en ik hoop dat het goed met jullie gaat. Prof.dr. R. de Wit, beste Rianne, 
je was al aanwezig bij mijn sollicitatiegesprek in 1999 bij de afdeling neuro-oncologie. 
In 2000 kreeg ik ook de kans om bij het PKC te komen werken. Ik heb een fi jne tijd 
gehad, veel van je geleerd. Jouw enthousiasme en vertrouwen waren zo aanstekelijk dat 
ik de drempel om promotieonderzoek te gaan doen durfde te nemen. Dr. M.A. Echteld, 
beste Michael, bedankt voor je begeleiding en de heftige discussies die altijd goed werk 
opleverden. 
Met veel plezier ging en ga ik na mijn werk, mede dankzij de fi jne kamergenoten door 
de jaren heen. Bedankt Erna, Michael, Silvia en Johan. 
Alle patiënten die meegedaan hebben aan de diverse onderzoeken wil ik bedanken 
voor hun inzet en tijd.
Alle stafl eden en (oud)-fellows van de afdeling interne oncologie, bedankt voor de 
samenwerking en de inclusie van de patiënten.
Irma, Tilly, Helen, Monique, Helma, Tineke, Hetty, Brenda en Astrid bedankt voor jullie 
inzet voor de patiënteneducatie tijdens de interventiestudie. 
Verpleegkundigen en medewerkers van afdeling B1, bedankt voor jullie gezelligheid, 
de gelegenheid om koffi  e te mogen drinken op de afdeling en de belangstelling voor 
mijn onderzoek.
Verpleegkundigen van het Behandelcentrum bedankt voor jullie inzet en belangstel-
ling voor het onderzoek, maar zeker ook voor de mogelijkheid om even stoom af te 
blazen of afl eiding te zoeken.
Dames van het secretariaat interne oncologie, bedankt voor de secretariële onder-
steuning. Een speciaal bedankje voor Marja. Ook al ben je de secretaresse van Karin, je 
geeft mij het gevoel erbij te horen. Bedankt voor je ondersteuning, maar nog meer voor 
de contacten en weetjes van de afdeling. 
Dames van het CMA, bedankt voor jullie medewerking voor het verkrijgen van de vele 
patiënten statussen. 
Dames van poli, bedankt voor jullie steun en medewerking aan alle projecten op de 
polikliniek.
Hans Kneefel, bedankt voor alle grafi sche ondersteuning van de fi guren uit hoofdstuk 
5 en alle posters die in de loop der jaren door jou afgeleverd zijn. 
Jitske Bruinix en Petrine Vogelaar van de bibliotheek in de Daniel, hartelijk dank voor 
jullie adviezen en snelle service. 
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Aan alle co-auteurs, bedankt voor de samenwerking en jullie bijdrage aan de manus-
cripten. 
Naast mijn werk in het Erasmus MC, vind ik het leuk om ook breder met het vak bezig te 
zijn. Bedankt collega’s en medebestuursleden van V&VN Oncologie en V&VN Pijn. 
Naast het werk vind ik al jaren afl eiding in de korfbal. Vaste teammaatjes: Angela, 
Sandra, Maarten, Serge, Remco en Dave, bedankt voor de afl eiding, gezelligheid en 
‘bewegingstherapie’.
Lieve papa en mama, fi jn dat ik altijd op jullie kan terugvallen. Jullie stonden en staan 
altijd voor mij klaar. Ik ben blij met jullie als ouders en wil jullie bedanken voor alles wat 
jullie voor mij hebben gedaan.
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Summary of PhD training and teaching activities
Name PhD student: WH Oldenmenger PhD period: 2005 - 2012
Erasmus MC Department: Medical Oncology Promotor(s): Prof. dr. CCD van der Rijt
Research School: MolMed Supervisor: Prof. dr. CCD van der Rijt
1. PhD training
Year Workload (ECTS)
General academic skills 
- Biomedical English Writing and Communication 2002 4.0 ECTS
- Academic Writing in English of PhD students 2007 1.0 ECTS
- NWO Talentendagen 2007 0.2 ECTS
- NWO Talentendagen 2009 0.2 ECTS
Research skills
- Classical Methods for Data-analysis. Nihes. Erasmus MC. 2004 5.0 ECTS
-  Basiscursus regelgeving en organisatie voor klinisch onderzoek-
ers (BROK)
2010 1.0 ECTS
In-depth courses (e.g. Research school, Medical Training)
-  Methodologie van patiëntgebonden onderzoek en voorbereiding 
van subsidieaanvragen. CPO Erasmus MC.
2009 0.2 ECTS
-  Short Introduction Course on Statistics & Survival Analysis for 
MD’s
2010 0.4 ECTS
Oral Presentations
- 16th ECCO/ ESMO congress 2011 1.0 ECTS
- Nursing Research Network, Erasmus MC 2011 1.0 ECTS
- IKNL, locatie Rotterdam 2011 0.4 ECTS
- Scientifi c Meeting Dept. of Medical Oncology Erasmus MC 2010 1.0 ECTS
- 6th EAPC research congress 2010 1.0 ECTS 
- Nationaal Congres Palliatieve Zorg 2009 2.0 ECTS
- Agora meeting 2008 1.0 ECTS
- Oncologiedagen 2007 1.0 ECTS
- Oncologiedagen 2007 1.0 ECTS
- Agora meeting 2007 1.0 ECTS
- Bijscholing verpleeghuisartsen 2007 1.0 ECTS
- Symposium Wondpijn 2006 1.0 ECTS
- Symposium Kenniscentrum Palliatieve Zorg Rotterdam 2006 1.0 ECTS
Poster Presentations
- 12th EAPC congress 2011 1.0 ECTS
- Oncologiedagen 2009 1.0 ECTS
- 11th EAPC congress 2009 1.0 ECTS
- 12th World Congress on Pain 2008 1.0 ECTS
- 10th EAPC congress 2007 1.0 ECTS
- 9th EAPC congress (April 2005, Aachen, Germany) 2005 1.0 ECTS
- Congres Vereniging van Oncologie Verpleegkundigen 2004 1.0 ECTS
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International conferences
- 16th ECCO/ ESMO congress (2011, Stockholm, Sweden) 2011 0.5 ECTS
- 12th EAPC Congress (2011, Lisbon, Portugal) 2011 0.5 ECTS
-  6th EAPC Research Congress (2010, Glasgow, United Kingdom) 2010 0.2 ECTS
- 7th EONS Spring Convention (2010, Den Haag) 2010 0.2 ECTS
- 11th EAPC Congress (2009, Vienna, Austria) 2009 0.5 ECTS
-  12th World Congress on Pain (2008, Glasgow, United Kingdom) 2008 1.0 ECTS
- 10th EAPC Congress (2007, Budapest, Hungary) 2007 0.5 ECTS
- 9th EAPC Congress (2005, Aachen, Germany) 2005 0.5 ECTS
Seminars and workshops
-  Autumn Symposium: Quality of Life. Consultatiecentrum voor 
Patiëntgebonden onderzoek, Erasmus MC.
2008 0.2 ECTS
-  Symposium Pijn, IKR werkgroep Pijn (November 2008 Ridderkerk) 2008 0.1 ECTS
- Enursing course. Pijn bij kanker. 2007 1.0 ECTS
-  5e Onderzoeksforum Palliatieve Zorg NL-VL. (November 2007, 
Antwerpen, België)
2007 0.2 ECTS
- Evidence-based Richtlijnontwikkeling (EBRO) 2006 0.2 ECTS
Other
- Nationaal Congres Palliatieve Zorg 2010 0.5 ECTS
- Nationaal Congres Palliatieve Zorg 2008 0.5 ECTS
- Verpleegkundig congres “tijd voor palliatieve zorg” 2008 0.3 ECTS
- 3th Nationaal pijncongres 2008 0.3 ECTS
- 26th V&VN Oncologie congres 2007 0.5 ECTS
- 25th V&VN Oncologie congres 2006 0.5 ECTS
- Nationaal Congres Palliatieve Zorg ( 2006 0.5 ECTS
- Wondpijn congres 2006 0.3 ECTS
2. Teaching activities
Year Workload (ECTS)
Lecturing
-  Specialistische verpleegkundige vervolgopleiding hemato-
oncologie. Pijn. Rotterdam.
2005-2011 3.0 ECTS
-  Specialistische verpleegkundige vervolgopleiding 
decubitus en wondverpleging. Pijn. Rotterdam.
2006-2008 0.6 ECTS
-  Specialistische verpleegkundige vervolgopleiding mam-
macare. Pijn. Rotterdam.
2005-2006 0.4 ECTS
-  Specialistische verpleegkundige vervolgopleiding 
oncologie. Pijn. Rotterdam.
2005-2008 1.0 ECTS
-  Specialistische verpleegkundige vervolgopleiding 
oncologie. Pijn. IKW Leiden.
2005-2006 0.5 ECTS
Supervising Master’s theses
- PJ de Raaf 2008 1.0 ECTS
- L Voets 2009 3.0 ECTS
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Wendy Oldenmenger werd geboren op 11 september 1974 te Deventer. In 1993 be-
haalde zij haar VWO-diploma aan het Geert Groote College te Deventer. In datzelfde 
jaar startte zij met de studie HBO-Verpleegkunde aan de Rijkshogeschool IJsselland 
te Deventer, waar zij in 1997 afstudeerde. Vervolgens studeerde ze van 1997 tot 1999 
Gezondheidswetenschappen aan de Universiteit van Maastricht te Maastricht met als 
afstudeerrichting Verplegingswetenschap. 
Aansluitend werkte zij van 1999 – 2004 als research verpleegkundige pijn bij de 
afdeling neuro-oncologie in het Erasmus MC – Daniel den Hoed, gecombineerd met 
een baan als onderzoeker bij het Pijnkenniscentrum van het Erasmus MC te Rotterdam. 
Hier werd haar interesse in pijn bij patiënten met kanker ontwikkeld. In 2004 kreeg zij de 
kans om een onderzoek op te zetten om de pijnbehandeling voor patiënten met kanker 
op de polikliniek te verbeteren. Vanaf 2004 kreeg zij voor dit promotieonderzoek, zoals 
beschreven in dit proefschrift, een aanstelling bij de afdeling interne oncologie van het 
Erasmus MC. Momenteel werkt zij, naast haar onderzoekstaken, als projectcoördinator 
voor het innovatieproject: ‘Detectie en behandeling van pijn bij kanker’ en als coördina-
tor van het Kenniscentrum Palliatieve Zorg Rotterdam bij de afdeling interne oncologie.
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